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ABSTRACT

The goal of the field of Bioengineering has always been to bring about a better standard
of care for patients. As a field encompassing a broad array of researchers and talents,
such improvements often are brought about through the integration of different fields.
This work advances the integration of controlled delivery and chemotherapy. The use of
cytotoxic chemotherapy has become and will continue to be a powerful tool for the
treatment of solid malignancies. Conventional dose scheduling of cytotoxic agents and
newer biological response modifiers are investigated under a clinical paradigm initially
designed to identify a drug dose that elicits acceptable levels of toxicity before the
rigorous testing of efficacy.

Newly developed regimens involving altering of the

conventional scheduling are always compared to the current “gold standard” of
chemotherapy. This process of evaluation becomes quite cost prohibitive through the
number of clinical trials required, and often the “clinically meaningful endpoint” is no
longer overall survival, but some more specific event, e.g. the targeted death of a specific
type of cell. The traditional method for evaluating new anti-cancer drugs is appropriately
intended to minimize patient toxicity and optimize safety. However, the inherent flaw in
this approach is that the effective dose and the toxic dose are often not concurrently
considered (e.g. the therapeutic index); rather, the approach is geared toward maximizing
death of a particular cell type. That is, the traditional approach is to provide the maximum
tolerated dose at defined time intervals; the intervals allow recovery of the normal tissue
but they also provide time for tumor cell regrowth and potential chemo-resistance.
Another obstacle is the conventional (intravenous) routes of administration which often
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expose the tumor to relatively short durations of drug, based on half-lives at excessively
high systemic levels; toxicity is cumulative and associated with high systemic levels of
drug.

The theoretical benefits of controlled drug delivery can minimize significant

fluctuations in systemic toxicity while optimizing efficacy. Such controlled therapy
requires a defined therapeutic index and a delivery platform that can be tailored to meet
the desired clinical endpoint. As understanding of cancer has grown, novel strategies
have been developed to selectively administer conventional chemotherapy to manage
advanced cases of solid malignancies that historically have a poor prognosis. The largest
obstacle to the use of such approaches is the dearth of technology for delivering a
chemotherapeutic in a repeatable controlled manner. To date, there is a paucity of
existing biomaterials whose properties allow (1) in situ gelation kinetics that can be
modulated to produce a predictable and sustainable drug delivery depot, (2) the ability to
control in situ gelation kinetics to maximize vascular and micro-vascular access to the
tumor, (3) predictable controlled release kinetics and duration of release in concert with
the total drug load to minimize dose dumping and maximize release, (4) and modulated
absorption kinetics to minimize collateral damage to healthy tissue and facilitate repeat
administration based on tumor response or treatment requirements.

At Poly-Med Incorporated, the OC Polymer system was specifically designed to combat
current issues with chemotherapy. These polymers, when combined in a novel delivery
system, allow localized controlled delivery.

The system advanced in this work is

comprised of the OC polymer, solubilized in a low molecular weight polyethylene glycol,
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and further absorbable polymers to help modulate release. This system is injectable
through a standard Leur-Lok needle and syringe system and forms a stable depot after
injection into an aqueous environment. The primary objective of the work was to test the
OC delivery system in an in vitro and an in vivo setting, laying the foundation for
investigation of this system in multiple chemotherapeutic treatments. The specific aims
of the project were to (1) determine the potential efficacy of the system through the
performance in in vitro studies to determine release characteristics with a model drug; (2)
ensure the relevancy of the results to a chemotherapy-based system through further in
vitro testing with the platinum-based chemotherapeutic carboplatin; and (3) exhibit the
clinical potential of the product through in vivo testing of a promising OC system in two
administration methods using a mouse flank model.

The OC polymer system was examined for release in vitro and was shown capable of
release of a water-soluble model drug from 3 days to greater than 45 days. Also, the OC
system was shown capable of release of the chemotherapeutic carboplatin in a relatively
linear manner over a period of 3 weeks, the course of a typical chemotherapeutic
regimen.

Finally, the OC polymer system was examined in an in vivo model and

tolerance of the non-drug loaded system was exhibited. Also, mice were shown to
tolerate higher levels of total carboplatin exposure than the literature suggested LD50 of
150 mg/kg. The next steps in preparing such a system involve further in vitro studies and
in vivo testing to validate the efficacy of such a system prior to clinical trials.
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PREFACE

This dissertation describes the development of a drug delivery system through the early
stages of design, in vitro testing and in vivo screening. The chapters each represent a
different stage of that process, and are outlined in the
Figure provided. Chapter 1 provides a general
overview of cancer and chemotherapy. Specifically,
many different chemotherapy agents are reviewed for
clinical significance. Chapter 2 further elucidates the
background of the field through a review of
oncological methods. New and novel methods and
technologies are reviewed. Chapter 3 provides the
background on the OC system iteself. The polymers
involved are discussed and characterized, and a
representative polymer is advanced. In Chapter 4,
release is explored from the OC system, with the
model drug doxycycline. Release is studied from
many different configurations of the system, showing
the modularity of the platform as a whole. Chapter 5 further illustrates the modularity of
the system with the use of many different pharmacuetics in regards to release. These
studies were designed to show the many different indications for which the system can be
used. Finally, Chapter 6 details the in vivo work performed. Preliminary studies, assay
exploration and a maximum tolerated dose study are all recorded to lay the ground work
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for a future full-scale animal study. Portions of many of these chapters have been
published in the following:

“Intravaginal Drug Delivery” in Polymers for Vascular and Urogenital Applications
(S.W. Shalaby, K.J.L. Burg, W.S. Shalaby, eds.) J. M. Olbrich, W.S. Shalaby, G.H.
Hilas. Taylor & Francis Group, LLC (2012)

“Injectable In Situ Forming Controlled Release Implant Composed of A Poly-EtherEster-Carbonate and Applications in the Field of Chemotherapy” J. Olbrich, P. Tate, J.
Corbett, J. Lindsey, III, S. Nagatomi, W. Shalaby, S. Shalaby Journal of Biomedical
Materials Research A (2012) 2012 Sep;100(9):2365-72

“Development and Utilization of Reversed Phase High Performance Liquid
Chromatography Methods for a Series of Therapeutic Agents” J. Olbrich and J. Corbett
Modern Chemistry & Applications (2013) 1:2

viii

TABLE OF CONTENTS

Page
TITLE PAGE .................................................................................................................... i
ABSTRACT ..................................................................................................................... ii
DEDICATION ................................................................................................................. v
ACKNOWLEDGMENTS .............................................................................................. vi
PREFACE ..................................................................................................................... vii
LIST OF TABLES ......................................................................................................... xii
LIST OF FIGURES ......................................................................................................xiii
CHAPTER
I.

CANCER AND CHEMOTHERAPY ............................................................ 1
Introduction .............................................................................................. 1
Types of Cancer ....................................................................................... 4
Chemotherapeutic Agents ...................................................................... 12
Tumor Microenvironment and Growth .................................................. 26

II.

TUMOR TREATMENT IN MODERN MEDICINE .................................. 33
Tumor Treatment and Administration Methods .................................... 33
Extension – What Next? ........................................................................ 44

III.

THE OC SYSTEM: A METHOD FOR LOCALIZED SUSTAINED
DELIVERY............................................................................................ 48
Overview ................................................................................................ 48
Polymers ................................................................................................ 50
Diluent.................................................................................................... 57
Additives ................................................................................................ 59
Injectability Checks ............................................................................... 60
Strengths of Such a System.................................................................... 62

ix

Table of Contents (Continued)
Page
IV.

DELIVERY OF MODEL HYDROPHILIC DRUG AND EVALUATION OF
VARIABLES THEREIN ....................................................................... 64
Introduction ............................................................................................ 64
Liquid OC Comparison .......................................................................... 68
Solid OC Release Profiles ...................................................................... 73
Additive Use – A6 ................................................................................. 74
SW Polymer Additives .......................................................................... 80
BTO3 Additive....................................................................................... 84
Diluent Effect on Release ...................................................................... 85
Blending of OCs and Effect on Release ................................................ 89
Conclusion ............................................................................................. 93

V.

RELEASE OF OTHER DRUGS FROM THE OC SYSTEM; USE OF
REVERSE PHASE HIGH-PERFORMANCE LIQUID
CHROMATOGRAPHY ........................................................................ 94
HPLC ..................................................................................................... 95
HPLC System and Parameters ............................................................... 97
Method Development: A General Outline ............................................. 97
Antibiotics, the OC System, and Clinical Need ................................... 101
Cefuroxime .......................................................................................... 101
Clindamycin ......................................................................................... 105
Dicloxacillin ........................................................................................ 108
Metronidazole ...................................................................................... 111
Paclitaxel .............................................................................................. 115
Tobramycin .......................................................................................... 119
Carboplatin ........................................................................................... 123
Conclusion ........................................................................................... 126

VI.

THE USE OF THE OC SYSTEM TO DELIVER CARBOPLATIN IN AN
ATHYMIC NUDE MOUSE MODEL................................................. 128
The Murine Model and the Relation to the OC System....................... 128
Preliminary Work................................................................................. 131
Cell Culturing and Testing of Efficacy with Carboplatin Eluents ....... 145
Full Pilot Study .................................................................................... 146
Discussion ............................................................................................ 156

VII.

CONCLUSIONS........................................................................................ 164

x

Table of Contents (Continued)
Page
VIII.

RECOMMENDATIONS FOR FUTURE WORK .................................... 166

BIBLIOGRAPHY ........................................................................................................ 168

xi

LIST OF TABLES

Table

Page

3.1

The OC Polymerization: A General Procedure ........................................... 52

3.2

Pertinent Properties of OC9 Lot 1 Purified.................................................. 56

3.3

Injectability of Multiple Polymers in Differing
Diluent Percentages ............................................................................... 61

4.1

Optimized Gradient HPLC Method for Detection
of Doxycycline ....................................................................................... 65

4.2

Partial Mass Balance Evaluation of Drug Release
from the Liquid OC Systems ................................................................. 72

5.1

Percent Inhibition of S. Aureus by Cefuroxime Eluents ............................ 105

5.2

Percent Inhibition of S. Aureus by Clindamycin Eluents .......................... 108

5.3

Percent Inhibition of S. Aureus by Dicloxacillin Eluents .......................... 110

5.4

Percent Inhibition of V. parvula by Metronidazole Eluents ...................... 115

6.1

Results of Preliminary Animal Studies ...................................................... 144

6.2

Groups and Subjects for the Pilot Study .................................................... 146

6.3

Subject Weights during Course of Study ................................................... 148

6.4

Results of GPC Data from Mice Within The Study .................................. 149

6.5

Selected Results of CBC Testing (Cell Count) .......................................... 151

6.6

Selected Results of CBC Testing (White Blood Cell Makeup) ................. 152

xii

LIST OF FIGURES

Figure

Page

1.1

Methotrexate, the original chemotherapeutic (Source
www.chemicalbook.com) ........................................................................ 2

1.2

Carboplatin, the second generation member of the
platinum drug family (Source: www.chemistry.about.com) ................. 14

2.1

Example configuration of a liposome
(Source: www.thescientist.com) .......................................................... 39

2.2

Example of a thermogelling system280......................................................... 43

3.1

Theoretical mechanistic diagram of OC system introduction
into an aqueous environment. ............................................................... 49

3.2

Complex viscosity over time for gelation of OC polymer
and organic solvent ............................................................................... 55

3.3

Theoretical demonstration of mechanism of large molecular
weight additive interaction with depot formation. ................................. 59

4.1

Example chromatogram of doxycycline HPLC run..................................... 66

4.2

Example of doxycycline standard curves utilized
throughout study .................................................................................... 67

4.3

Doxycycline release from the liquid OC polymers...................................... 69

4.4

Release profiles of the solid OC polymers ................................................. 73

4.5

Effect of doxycycline release from OC2 system and the effect
of A6 inclusion ....................................................................................... 75

4.6

Effect of doxycycline release from OC4 system and
the effect of A6 inclusion ....................................................................... 76

4.7

Effect of doxycycline release from OC6 system and the
effect of A6 inclusion............................................................................. 77

xiii

List of Figures (Continued)
Figure

Page

4.8

Effect of doxycycline release from OC9 system and the
effect of A6 inclusion............................................................................. 78

4.9

The effect of the SW family of additives on release from
the OC9 delivery system ........................................................................ 81

4.10

Comparison of A6 and SW2: effect on DOX release from
OC9 ........................................................................................................ 82

4.11

Release of DOX from OC9/SW2 system over 42 days with
line of best fit ......................................................................................... 83

4.12

Effect of doxycycline release from OC4 system and release
difference between BTO3 and BTO3S .................................................. 84

4.13

Comparison of DOX release from OC9 system between
PEG and G4A diluents ........................................................................... 86

4.14

Effect of doxycycline release from OC4 systems with
varied diluents ........................................................................................ 87

4.15

Comparison of DOX release from OC9 system between a
67/33 and 50/50 system of G4A ............................................................ 88

4.16

Comparison of DOX release from blended OC systems ............................. 90

4.17

Comparison of DOX Release from OC Blends ........................................... 91

4.18

Comparison of DOX release from OC blends of differing
diluent composition................................................................................ 92

5.1

A 5-95% run of cefuroxime on HPLC ......................................................... 98

5.2

A first attempt at a “15% method” for cefuroxime ...................................... 99

5.3

Acceptable method for cefuroxime analysis on HPLC.............................. 100

5.4

Cefuroxime standard curve at 275 nm ....................................................... 102

xiv

List of Figures (Continued)
Figure

Page

5.5

Release of cefuroxime from OC4 gel systems ........................................... 103

5.6

Clindamycin standard curve at 210 nm ..................................................... 106

5.7

Release of clindamycin from OC4 gel systems ......................................... 107

5.8

Dicloxacillin standard curve at 225 nm ..................................................... 109

5.9

Release of dicloxacillin from OC4 gel systems ......................................... 110

5.10

Metronidazole standard curve at 275 nm ................................................... 112

5.11

Release of metronidazole from OC4 gel systems ...................................... 113

5.12

Paclitaxel standard curve at 230 nm .......................................................... 117

5.13

Paclitaxel extraction efficiency study ........................................................ 118

5.14

Tobramycin standard curve at 254 nm....................................................... 120

5.15

Tobramycin time complex stability study.................................................. 121

5.16

Release of tobramycin from OC4 gel systems ........................................... 122

5.17

Carboplatin standard curve at 240 nm ....................................................... 124

5.18

Release of carboplatin from OC9 gel systems ........................................... 125

5.19

Release of carboplatin from an OC9/PEG/SW2 gel system ...................... 126

6.1

Image of depot deposited in Mouse A (24 hours post injection) ............... 134

6.2

Liver from Mouse A swollen and visibly diseased .................................... 135

6.3

Hind flank placement of polymer depot (Mouse B 6 days
post implantation) ................................................................................ 137

6.4

Mouse B following euthanasia (21 days post implantation) ...................... 138

xv

List of Figures (Continued)
Figure

Page

6.5

Mouse C at sacrifice (6 days post implantation) ........................................ 139

6.6

In clockwise order from top-left (1) Mouse D kidney at 40x
(2) Mouse D kidney at 10x (3) Mouse D liver at 10x (4)
Mouse D liver at 40x........................................................................... 140

6.7

GPC results of OC system following mixing but prior to
injection................................................................................................ 141

6.8

GPC results of OC system extracted from murine model.......................... 142

6.9

GPC results of neat OC9 polymer ............................................................. 142

6.10

GPC results of neat PEG 400 ..................................................................... 143

6.11

GPC Results of neat SW2 (no peak present) ............................................. 143

6.12

Liver histology images (H&E staining) of mice 1, 5, 9, 16,
and 20. Images are displayed clockwise in numeric
order with mouse 1 in the top-left corner.
(10x objective magnification) ............................................................ 154

6.13

Kidney histology images (H&E staining) of mice 1, 5, 9, 16,
and 20. Images are displayed clockwise in numeric order
with mouse 1 in the top-left corner.
(10x objective magnification) .............................................................. 155

xvi

CHAPTER ONE
CANCER AND CHEMOTHERAPY
Introduction
One malady has hung over society more than any other in the history of modern
medicine. Cancer has seen a steady increase over the years; one out of every two
children born today will be diagnosed with the disease at some point in their lives1.
Malignant tumors can manifest in almost any system in the human body and, untreated,
will metastasize to other organs and tissues leading inevitably to death of the host. The
mortality of the disease and the lack of a “cure” lead to the vital necessity of effective
treatments. Treatments will vary slightly depending on the area of affliction; however
they commonly consist of surgery, radiation and chemotherapy2. Surgery is the first line
of defense against most operable tumors and is usually at least partially effective against
localized, relatively early stage cancers3,4. However, in patients with recurrent tumors or
tumors in inoperable areas, chemotherapy is indicated or possibly the only option3,5.

Chemotherapy has evolved over the years, and is generally considered to originate in the
period surrounding World War II (1939-1945). After observing rapid tissue growth
brought on by unchecked cell proliferation, Louis Goodman and his group at Yale
University investigated means to slow this phenomenon6. The effect of a toxic agent
used in the war, mustard gas, was studied and found to retard the growth. Concurrently, a
group at Harvard University examined means with which to synthesize antagonists for
tumor growth.

Their work culminated with the development of one of the first
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synthesized folic acid antagonists, aminopterin7.

This discovery lead to significant

success in treating lymphomas and pediatric acute leukemia.

Despite the evidence presented in Farber’s publication, skepticism remained prevalent in
the field toward the effectiveness of aminopterin and the next generation amethopterin. It
took fully a decade more before solid evidence came forward describing the effectiveness
of these antagonists, specifically amethopterin (modern methotrexate) in combating
unrestricted cellular growth8. More significant than the proof of folic acid antagonists
was the fact that researchers at the National Cancer Institute were able to force a solid
tumor into remission for the first time using chemotherapeutic agents. Methotrexate
(Figure 1.1) is still used to this day in combating choriocarcinoma9.

Chemotherapeutics became an area of intense interest for research, both public and
private. The first alkaloid chemotherapeutic, Vinblastine, was independently developed
in 1958 at both Eli Lilly and the University of Western Ontario10. The alkaloid group of
drugs was significant because their
mechanism of action differed from that
of methotrexate in that they interfered
with tubulin.
microtubule
Figure 1.1: Methotrexate, the original
chemotherapeutic (Source
www.chemicalbook.com)

This in turn disrupted
production

during

mitosis, and hence retarded cellular
reproduction. This development gave
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rise to a revolution in the field of chemotherapeutics, leading to drugs designed to
interfere with the mitotic process rather than design of simple antagonists such as
methotrexate.

The next key breakthrough in the development of chemotherapy was the concept of
combination therapy, or the use of multiple drugs against a single tumor. Combination
therapy relies on the principle of “multiple pathways”, meaning that, should an individual
tumor develop a resistance or immunity to a certain type of chemotherapeutic, the
treatment paradigm also contains a complimentary drug that acts through a differing
mechanism. In this way the tumor is theoretically always subjected to an effective
chemotherapeutic drug.

However, even with combination therapy, large volume or advanced stage disease would
be refractive to treatment. Time and time again it has been proven that chemotherapy is
more effective against smaller groups of cells, perhaps because most chemotherapeutic
agents are more effective against mitotic cells than cells in the resting phase11 and larger,
more developed tumors will have a smaller percentage of cells undergoing mitosis at any
one time. Due to the relative ineffectiveness of chemotherapeutics in affecting medium
and advanced stage tumors, chemotherapy is often combined with other methods 12. This
combination is referred to as adjuvant therapy, which infers any combination of surgery,
chemotherapy, radiotherapy, or hormonal therapy to combat cancerous growths.
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Adjuvant therapy is the modern primary care paradigm for most operable tumors such as
melanoma, colon cancer and prostate cancer, amongst others11,12,13.

Modern chemotherapy revolves around adjuvant therapies with multiple different drugs.
Over the years, different families of chemotherapeutic drugs have been developed. Some
of the more commonly used among these are the taxanes, anthracyclines, and platinumbased drugs. Upon diagnosis, attending physicians design the best course of treatment
for each individual and choose the components of adjuvant therapy and the drugs used
based on previous clinical data.

Types of Cancer
Proper and prompt diagnosis of cancer is the most vital step in combating the disease.
Local cancers have been documented as appearing in almost every organ in the human
body. Of all cancers diagnosed in the United States, at least one out of every two is
defined as lung, female breast, prostate, or colorectal14. These cancers are colloquially
referred to as the “Big 4” cancers. Appropriately, a significant portion of research and
development funding is directed at each of these diseases.

Lung cancer affects nearly 7% of the American population during their lifetime according
to 2011National Cancer Institute statistics1. Lung cancer is divided into Small Cell Lung
Carcinoma (SCLC) and Non-Small Cell Lung Carcinoma (NSCLC). NSCLC accounts
for 70-80% of diagnosed cases and is usually relatively advanced at the time of
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detection15. Due to the nature of the disease, specifically the presentation of a tangible
tumor, surgery is usually the primary mode of treatment16. However, this treatment only
results in a 20 to 30% survival rate. Early detection and adjuvant therapy including
radio- or chemotherapy can improve this rate, but NSCLC mortality rates remain high
even with such treatment. Chemotherapeutic agents used in conjunction with surgery
include taxane, pyrimidines, camptothecin analogues, vinorelbine, and platinum
combinations thereof17. SCLC is more difficult to operate upon and responds better to
primary chemotherapy than NSCLC, with upwards of a 45% survival rate. Surgery can
be used as an adjuvant therapy in cases of SCLC, but is not common18.

While lung cancer is the leading cause of death by cancer in males, breast cancer claims
more females every year than any other form of cancer1. Breast cancer usually manifests
itself within the mammary areas of the breast. As recently as 1980, the main method for
treatment was mastectomy, in which the cancerous portion of the breast was removed as
well as a majority of the surrounding tissue, the latter as a prophylactic measure19. Due
to the high public profile of the disease, a large amount of funding and research targets
this area. Through research and the advent of screening technologies, multiple new
avenues are available for treatment, and mastectomy has been restricted to preventative
measures and “last resort” cases.

Simple radiotherapy or primary chemotherapy is

capable of inducing tumor remission or at least requiring only a partial mastectomy,
leaving a cosmetically acceptable breast4, 20. Early screening procedures have provided
the largest opportunity to combat breast cancer non-operatively, by allowing
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chemotherapeutics to be used in the early stages of the disease21. Indeed, the paradigm
for treating breast cancer calls for early detection and primary treatment with drugs such
as doxorubicin or paclitaxel22. If the primary treatment is not entirely successful, surgery
can be used to augment chemotherapy; this approach is called neoadjuvant therapy23.
Other less traditional treatment mechanisms include hormonal therapy, oral
chemotherapy, and anti-angiogenesis therapy24,

25

.

Each of these treatments, while

originating in breast cancer treatment, is beginning to gain traction in other areas of
cancer research.

The third “Big 4” cancer is cancer of the prostate. Affecting mainly the male organ used
in reproduction, this disease will affect 16% of men at some point during their lives1.
Myriad prostate cancer treatments have been developed over the years, but few have been
proven repeatedly effective26. The most common primary treatment is surgery27. The
procedure, radical prostatectomy, is intended to remove or reduce the cancerous tissue28.
Other options range from hormonal therapy, to radio therapy, to active non-action
(“Watchful Waiting”)

29

. Chemotherapy has been largely ineffective in the realm of

prostate cancer, but recent studies with the taxanes have shown promise30. Because of
the absence of effective chemotherapy, the leading adjunctive therapy is hormonal.
Hormonal therapies, such as those including antiandrogens, are as effective as castration
in arresting prostate cancer31. The quality of life advantages of this treatment far exceed
castration, in at least the obvious matter of retaining sexual function. However, the
largest recent contribution to the battle against this disease has come in the form of
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enhanced screening and early detection. Prostate-specific antigen (PSA) is a protein, the
level of which can be monitored to allow extremely early detection of prostate
problems32. Over half of prostate issues detected by this mechanism can be readily
treated. Cancer allowed to progress past this stage, often to hormone refractory prostate
cancer which cannot be treated by castration or hormone therapy, is often terminal. In
the absence of a highly effective treatment, early detection is by far the best available
practice for combating this disease.

The final, and perhaps least publicized, of the Big 4 cancers is colorectal cancer. In this
instance, carcinomas develop from polyps within the intestinal tract33. While not all
polyps will develop into carcinomas, the most effective way to treat colorectal cancer is
to identify and swiftly deal with those polyps which have the potential to proliferate in a
malignant manner. When early detection fails, colorectal cancer often leads to a poor
prognosis as the highly vascularized nature of the area allows quick and widespread
metastization33.

Many individuals are reluctant to undergo screening33, 34; this failure to

seek medical screening largely contributes to colorectal cancer’s moniker “the silent
killer”. When the disease is allowed to progress, surgery is the frontline treatment
prescribed in the majority of cases35, 36, 37. Prior to metastasis, when tumors are relatively
small, surgical treatment for colorectal cancer has a relatively high success rate35. This
success rate can be enhanced by radiologic imaging techniques which include barium
enemas prior to positron emission tomography (PET) 38. These radiographic techniques

7

are particularly useful in the colorectal arena due to the non-uniform nature of the lower
intestinal tract.

Secondary treatment, where surgery alone is not successful, usually focuses on adjuvant
therapy using chemo- or radiotherapy, with physicians often favoring anti-neoplastic
drugs37. The current paradigm of chemotherapy for colorectal cancer is seen in the form
of the drug 5-fluorouracil, a fluoropyrimidine which is capable of oral administration39, 40.
This drug, which disrupts deoxyribonucleic acid (DNA) replication and thus cell division,
has been shown to combat localized forms of colorectal cancer as well as metastasized
forms of the disease40. Accordingly, oral fluorouracil is often employed in conjunction
with surgery in frontline treatment for colorectal cancer, which is detected only at a late,
aggressive stage. Other chemotherapeutics have been developed39, mostly within the
fluoropyrimidine family, but 5-fluorouracil remains the chemotherapy of choice for
colorectal cancer.

Aside from the aforementioned “Big 4” group of cancers, carcinomas can manifest
themselves in almost any organ of the body. Perhaps the deadliest area for cancer to
develop is within the cranial cavity. Rarely developing spontaneously, brain cancer often
is the result of metastasis of another cancer, such as that of the breast or lung41, 42, 43, 44.
Unlike other cancers, surgery is only a viable option in about 25% of cases45. Lack of
suitability for surgical treatment49 means that chemotherapy43, 45 and, to a lesser extent,
radiotherapy42, are the frontline treatments for brain cancer. Indeed, chemotherapy is
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indicated for at least a portion of the primary therapy in up to 72% of brain cancer
cases46.

While the necessity of chemotherapy in cases of brain cancer is obvious, the
methodology is not. The lipophilic nature of the blood-brain barrier (BBB) is seen as a
deterring factor in the delivery of almost any water-soluble anti-neoplastic43 and, as such,
systemic delivery of lipophilic drugs will often preferentially deliver to sites other than
the brain47. To this end, direct injection and implantation of delivery vectors such as drug
loaded “wafers” have been investigated43, 47. Regrettably, even with these theoretically
more efficient methods, drug delivery to the brain remains difficult48. Great advances
will be needed in the coming decade to improve the poor mortality rates (around 80%)
associated with brain cancer50.

Brain cancer can occasionally be caused by the metastasis of ovarian cancer51. Ovarian
cancer is an important malady as it is the highest gynecological cause of death among
women52. While the origins of this disease are not fully understood, carcinomas in the
ovary and surrounding tissue are thought to stem from hormonal imbalances/inductions53.
Further complicating the issue is the high rate of metastasis and secondary cancers,
thought to be brought about by cellular transport through the lymphatic drainage system,
the latter which is prevalent in the gynecologic region54.
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Ovarian cancer treatments often use chemotherapy as a frontline option, due to the high
rate of metastasis and difficulty of surgery55. The current paradigm relies on the use of a
taxane, usually paclitaxel, in conjunction with a platinum drug56, 57, 58, 59. Other drugs,
such as doxorubicin, can be used as long as their toxicity levels are held in check60. One
such method for reducing toxicity that has been studied effectively in ovarian cancer is
dose-dense therapy61, 62, 63. This therapy relies on the shortening of the treatment window
and the use of lower doses of drug. Other treatments have been attempted, such as
administration of vascular endothelial growth factor (VEGF) or retinoid analogs in order
to circumvent traditional chemotherapeutic toxicity64, 65. However, these therapies have a
toxic effect, as is expected from almost any anti-angiogenic treatment66. Further work is
obviously needed as the prognosis for this disease is still poor throughout the world67.

Any discussion of cancers would be incomplete without inclusion of skin cancer, the
most common cancer in man68. While this disease is largely treatable, with lower than
average mortality rates among cancers, it will afflict large proportions of the population
during their lives69. While skin cancer is largely initiated by overexposure to ultraviolet
radiation in the form of sunrays, it can still afflict humans with higher proportions of
pigmentation in their skin69,70. Also, some sections of the population will be more
susceptible to developing the more malignant forms of this cancer based on genetic
disposition71. The deadliest form of skin cancer is a malignant melanoma.
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Malignant melanomas will account for less than 2% of cancers annually72, but if the
disease is not caught in the early stages, the 5-year survival rate shrivels to less than
10%73. If caught early, surgery and palliative treatment can often be enough to check the
growth of the tumor; however, as the disease progresses metastasis occurs72. Malignant
melanomas are among the most aggressive of all cancers in terms of metastasis, hence the
need for early detection and treatment73. Following this metastasis, there is still no clear
path for treatment as most therapies in use are poorly tolerated or produce unacceptably
low rates of success74. Therapies such as retinoid chemotherapy75 and molecular/gene
therapy76,77 have been used to attempt to combat melanoma metastasis. However, the
current benchmark for success uses systemic distribution of platinum or nitrosourea drugs
to attempt to halt and force recession of the aggressive cancer74. Due to the generally
poor prognosis, current detection is more important in this case than in almost any other
cancerous case, due to the dramatic difference between early and late detection survival
rates. Future work in the battle against metastasized melanomas will focus on more
effective administration of systemic chemotherapeutic/gene therapy.

For the past hundred years cancer has predominantly been treated with surgical
resection78.

However, a shift towards non-surgical techniques is occurring, with

promising results. More and more commonly, chemotherapy is being used to treat
cancer. Increases in lifespan and elimination of malignant tissue have been realized in all
age groups, even in pediatric groups79. Chemotherapy is administered in myriad ways,
including orally, intravenously, subcutaneously and intralesionally78, 79, 80. The treatment

11

can be used independently in the frontline, adjuvantly (following surgery), concurrently
with surgery or radiotherapy, or as a method of last resort (salvage therapy) 78, 79. The
delivery pathway and usage are determined through the cancer presented and the patient’s
disposition.

Chemotherapeutic Agents
Chemotherapy offers advantages over traditional surgical, and even radiological
techniques81.

These benefits largely stem from the mechanism of action, as

chemotherapy targets cells mainly during the proliferative stage. Thus, by interfering
with the reproduction of cells, the growth of large, fast-growing populations of cells can
be checked or the cells may even be forced to recede. One of the distinguishing elements
of tumor cells is that they reproduce more quickly than normal human cells. Therefore,
by administering an agent which disrupts cells during this phase of cell life, cancer cells
can be targeted preferentially over normal human cells. Because of this induction of cell
death, chemotherapeutics are often referred to as “cytotoxic drugs”78, 82.

It is important to understand the types of agents used to undertake this treatment, as they
all differ in properties and mechanism of action. While most act to disrupt cell division
in some way, different groups of drugs act in different manners. Similar to selecting an
antibiotic, choosing the correct drug often makes the difference between success and
failure of a given treatment. There are nine major families of cytotoxic drugs.
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Alkylating agents are among the most widely used chemotherapeutics, due to their broad
spectrum of action83, 84. This class of drugs, comprising mainly cyclophosphamide and
ifofsamide, acts mainly by covalently binding to exposed DNA, hence halting or
disrupting the replication of cells. These drugs are regarded for their large therapeutic
window85,86 which allows lessening of virulent side-effects during use.

Another

interesting attribute of these drugs is that their mechanism of action has been shown to be
catalyzed through an increase in heat; as increased temperature (hyperthermia) is often a
condition surrounding malignant tumors, this characteristic serves to increase the
alkylating

agent’s

effectiveness87.

Further

use

of

the

alkylating

agents,

cyclophosphamide especially, is in metronomic dosing. This dosing schedule entails the
use of a more frequent, less intense treatment. Cyclophosphamide has exhibited antiangiogenic properties which add even further to the effectiveness of the drug88. This
class of drugs is not without drawbacks, among which are low selectivity and targeting
ability for cancerous cells and the quick inducement of tumor resistance83. However,
numerous studies have shown one alkylating agent to be effective against tumor growth
once the tumor has become resistant to the other89. Thus these agents are indicated as
first and secondary treatments against a variety of cancers, including head and neck84,
non-small cell lung84, breast84,90, cervical94, soft-tissue91, bone93, uterine84 and ovarian
cancer84,92. These compounds are often used in conjunction with other cytotoxic drugs in
combination therapies91, 93.
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Another family of chemotherapeutics,
often used in combination with the
alkylating agents92, is the platinum
family of drugs. This family consists
of three generations of drugs. The first,
cisplatin, is among the most active
Figure 1.2: Carboplatin, the second
generation member of the platinum drug
family (Source:
www.chemistry.about.com)

agents used in the field95. The second
generation drug, carboplatin (Figure 2)
has fast gained notoriety as being much

more stable and as having fewer and milder side effects than cisplatin96. The third
generation, and most cytotoxic, platinum drug is oxaliplatin97, 98. While the mechanism
through which these drugs prove effective is not fully understood, it is theorized to
involve the binding of the eponymous platinum group of the drugs to DNA99, 100. The
bound drug then prevents translation and transcription, effectively halting mitosis. The
drawback of this family lies in its higher than normal systemic toxicity95 and the fact that
platinum resistance is inherent in many cancer lines95,

96

. This platinum resistance is

normally presented by the detoxification of the drug by the tripepetide glutathione, which
is normally tasked with mitigating metals101. However, oxaliplatin has been shown to be
efficacious where cis- carboplatins are found ineffective98, and all of the platinum drugs
can be combined with glutathione inhibitors to increase their effect101. These drugs are
administered through a wide range of routes, including intravenous, intraperitoneal, and
subcutaneous102. Because of the wide range of delivery options and a broad spectrum of
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action, platinum drugs are used in combination and single agent therapies for a wide
range of cancers, including but not limited to oral103, ovarian104, 105, lung99, biliary106 and
colorectal97, 98,107.

Another group of cytotoxic drugs developed out of everyday antibiotics. The anti-tumor
antibiotics work through DNA disruption, similar to the previously described groups, but
do so in non-covalent binding manners108. Cultivated from natural means, hence the
antibiotic distinction108,

109

, these are among the oldest anti-neoplastic drugs110. The

drugs included in the category include actinomycin-D, doxorubicin, and bleomycin.
While distinct for their wide range of efficacy, these drugs are also noted for their
exceptional systemic toxicity issues, even among chemotherapeutics109, 110. This toxicity
usually manifests in the areas of the heart and lung and poses a significant side effect
when used in systemic chemotherapy. Because of these toxicity issues and because of
the potential of the drugs against a wide range of cancers, much work has gone into
attempting to control this toxicity. The toxicity can be manipulated through methods
which center on specific targeting, such as intra-tumoral injection111 and polymer
conjugation112.

The most successful of these manipulations, however, involve the

liposomal encapsulation of doxorubicin, both pegylated113 (Caelix®) and unpegylated114
(Doxil®). This encapsulation not only limits the toxicity but also can increase drug
penetration into the tumor113. Regardless of the toxicity issues, this group of drugs is
used to combat almost any cancer known to man115-120.
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The group of anti-neoplastics, known as the anti-metabolites, contain some of the oldest
and the newest drugs in the battle against cancer. Methotrexate, in use since 19569, spans
many decades of drugs, from 5-fluorocil to recent purine analogs and conjugates.
Despite the vast time frame, these drugs all act to disrupt the protein cascade involved in
mitosis and thus prevent cell reproduction121,122,123. The disruption of the normal cell
cycle has allowed remission rates as high as 90%, in the case of methotrexate treatment
against some cancers124. The predominant issue with methotrexate lies in the associated
virulent side effects124, an issue that the use of 5-flourocil was meant to address123. The
even newer, more effective and less toxic pemetrexed has already become a consistent
choice for malignant pleural mesothelioma, a carcinoma of the lung tissue caused by
asbestos125.

Aside from the normal toxicity issues with chemotherapeutics, the anti-metabolites also
suffer from short exposure to the tumor microenvironment due to low retention and high
renal clearance126. Thus, these drugs require metabolic rates above a minimum threshold
to allow their mechanism of action to be effective, e.g. to halt the metabolic pathway127.
To this end, much thought has been placed into entrenching the individual drugs into the
target cells so they are not cleared from the environment123. Interestingly, methotrexate
and 5-flourocil have a synergistic effect on each other’s effectiveness, i.e. increasing
retention and penetration, and are thus often used sequentially128,

129

.

The anti-

metabolites are also often used in conjunction with other chemotherapeutics in
combination therapy130. Platinum-based drugs pair nicely with the anti-metabolites, as
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their mechanisms of action are different enough so as to not conflict131, 132. Also, folinic
acid has worked well with anti-metabolites, alone and in combination therapy132, 133. This
success is theorized to be due to the catalyzing effect that folinic acid has on metabolism,
thus enlarging the anti-metabolites window for action133.

Newer methods for enhancing the effectiveness of the anti-metabolites rely on
encapsulation and the purine analogs.

Liposomal encapsulation and nanoparticle

conjugation are means through which renal clearance can be lessened and targeting can
be strengthened126, 134. These methods hold much promise for this group, as their major
issues lie in these areas. Purine analogs attached to polymeric carriers also hold promise,
as they can exhibit anti-metabolic activity, thus theoretically turning a polymer into a
cancer fighting agent135.

These analogs attach to polymers, as well as other

chemotherapeutics such as platinum-based drugs136, opening the door of the antimetabolites to many other modes of action.

The platinum drugs also work in conjunction with another group of anti-neoplastics, the
microtubule inhibitors. The microtubule inhibitors are a group of cytotoxic drugs, named
for their mechanism of action, which inhibit mitosis through interference with the normal
production/reduction of microtubules during metaphase137, 138. The two main divisions of
drugs in this group are the taxanes and the vinca alkaloids. The commercially available
taxanes are paclitaxel and docetaxel, which are among the most active chemotherapeutics
against solid tumors139. The taxanes were originally identified from portions of yew
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trees, Taxus brevifolia and Taxus baccata respectively, but today most of the supply of
drug is synthetic140,

141

. As the mechanism of action for the taxanes is rather unique

amongst chemotherapeutics142, they are ideal for adjuvant therapy as the taxanes allows
effective therapy against cells in a larger range of the cell cycle139, 143,144.

The taxanes are not without drawbacks, however. Taxanes have several systemic toxicity
issues, including neural toxicity and hypertension145. Also, paclitaxel has an extremely
limited solubility in water146, making conventional release studies difficult147. Also, due
to the low water solubility, oil and emulsion vehicles are required for intravenous taxane
administration to the body148. The formulation for paclitaxel is traditionally Cremophor
EL®, while the solubulizer for doxetaxol is usually polysorbate 80141, while other solvents
and agents have been investigated148. With these thoughts in mind, any type of localized
delivery must be designed around these properties.

Devices such as coated stents,

microspheres, surgical pastes, biodegradable implants, and liposomes have been
investigated149, 150. Prodrugs, such as isotaxel, have been investigated as well to boost
water solubility and allow easier administration and targeting151.

The other, currently less popular, division of the microtubule inhibitors incorporates the
vinca alkaloids. Derived from the periwinkle plant Cantharanthus roseus, the first of
these microtubule inhibitors was discovered in the 1950s138,

152

.

This compound,

vinblastine, was the first drug which used the principle of interfering with tubulin,
symbolizing a shift in chemotherapy paradigm. The release of vinblastine was followed
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closely by the development of vincristine and, subsequently, vinorelbine and
vinflunine138.

With each iteration, systemic toxicity was reduced while anti-tumor

efficacy was increased153. Vinflunine, developed in the early 2000s, is now used as a
single agent therapy as well as in combination therapies against a wide range of solid and
metastasized cancers10. Chemically, the vinca alkaloids all share a common chemical
structure with only slightly differing side chains.

This difference has led to much

research into slight chemical modifications aimed at creating analogs of the alkaloids to
further reduce toxicity and boost efficacy152.

Research into drug modification has paid dividends in the past, as is exhibited by the
development of the topoisomerase inhibitors.

This family’s mechanism of action

revolves around the inhibition of the enzymes DNA topoisomerase I and II154,

155,156

Through this inhibition, mitosis is disrupted, and tumor growth is retarded.

These

.

antineoplastics are derived from the drug podophyllotoxin157 which has been used for
hundreds of years as a folk medicine but for which the anti-mitotic properties were
discovered within the past century154.

While podophyllotoxin proved to create

unacceptable toxic side effects, development work led to the discovery of the semisynthetic derivative etoposide in the 1950s.

Etoposide is still known to be a highly toxic drug, causing myelosuppression and
mucositis158. Due to the high efficacy and the long period of history of development,
much work has gone into quantifying the therapeutic window of etoposide159. Data
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indicates that antitumor activity begins as low as 0.5 ul/mL, and treatment can be
tolerated in a dose as high as 10 ug/ml160. This, still imprecise, quantification of the
therapeutic window is rare to find amongst chemotherapeutics and could eventually lead
to more effective treatment options for patients as more work is continuing on the topic.

This therapeutic window work has also led to further quantification of etoposide
properties which allow more unique usages of etoposide.

For example, thermal

characterization has been executed on etoposide and many of its derivatives161, allowing
further processing of the drug. Also, much microbiological analysis has proven capable
of identifying protein binding sites and methodology162. The ability to process the drug
at temperatures up to 300°C, along with the advanced elucidation of metabolic pathways,
allows novel formulation and administration such as phosphate prodrug forms163, but
perhaps more importantly as an oral form164. The oral form allows the use of outpatient
chemotherapy, which has been shown to be on par in terms of tumor response with in
hospital intravenous administration.

While etoposide works through inhibition of DNA topoisomerase II, two other drugs,
topotecan and irinotecan, work through inhibition of DNA topoisomerase I155, 156. These
drugs were developed as analogs of camptothecin, in a similar manner as etoposide was
an analog developed from podophyllotoxin. Topotecan is administered as a single agent
and in combination therapies quite effectively due to the synergistic activity it exhibits
with other antineoplastics such as the platinum drugs165. Also, the lipophilic nature of the
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drug allows it to cross the blood brain barrier easily, aiding in treating more dangerous
cancers such as that of the brain and spine166. It is not, however, immune to the side
effects that plague etoposide, being quite toxic to the nervous system167. Attempts to
limit this toxicity and increase the water solubility of the drug center around nanopreparations involving lipid and PEG preparations168, 169.

The other type II inhibitor, irinotecan, has become a frontline, single agent treatment for
colorectal cancer170,

171

.

This water soluble topoisomerase inhibitor follows a very

complex metabolic pathway to the form of its active metabolite SN-38172. However, this
metabolite is more toxic in some patients than are the other topoisomerase inhibitors173.
The reasons for this difference between patient groups have yet to be fully investigated,
however data collected is beginning to reveal clues174. Further investigation will allow
more accurate use of this effective drug.

Another drug of which not much is known is altretamine. The mechanism of action for
this drug has yet to be fully understood, however chemically it resembles members of the
alkylating agents175. This antineoplastic requires metabolic activation for its cytotoxic
effects to be activated176. Because of this requirement, altretamine is administered orally
so as to take greatest advantage of its properties177. Altretamine does not have high
success rates (10-20%) and so is often administered as a salvage therapy drug, a “drug of
last reasort”178, in malignant metastasized cancers such as ovarian which have proven
resistant to other more traditional treatments179.
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The side-effects associated with

altretamine target the digestive system, due to the metabolic requirement, and include
nausea and vomiting180.

Non-cytotoxic drugs have also found their way into the fight against cancer. Certain
cancers, such as that of the breast, are resistant to cytotoxic chemotherapy but respond to
other types of regimens. One such regimen involves the deprivation of certain hormones,
such as estrogen or androgens, in order to “starve” hormone-resistant tumors. The
majority of work in alternate regimens of this type has manifested itself in breast cancer
research, where up to approximately two-thirds of tumors are hormone-resistant181. This
research has produced two types of drugs, aromatase inhibitors (AI) and selective
estrogen receptor modulators (SERM), which are designed to slow growth of such
cancers.

Both of these drugs have applications, such as ovulation induction and

endometriosis treatment, outside tumor treatments,

182,183,184

. SERMs such as raloxifene

have been investigated in tumor regression, but tend to be overshadowed by the
aromatase inhibitors.

The aromatase inhibitors, for the quarter century prior to 2000, were dominated by
tamoxifen181.

Tamoxifen was developed quickly on the heels of the first AI,

aminoglutethimide, and greatly increased the efficacy of the class of drug185. Tamoxifen
and other AIs inhibit the enzyme aromatase, which is the key enzyme in estrogen
biosynthesis186.

Breast cancer is highly dependent on estrogen for sustenance and

replication. Thus, with use of AIs such as tamoxifen, breast cancer can be forced into
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remission in a wide range of cases187. In the past decade, two new AIs have come to
light. Anastrozole and letrozole, the third generation of AIs, have been shown in multiple
studies to be more effective than tamoxifen in combating growth of breast tumors188-191.
One such study even shows that letrozole can inhibit more than 99% production of
estrogen192. The ability to administer anastrozole orally makes the drug even more
attractive193. While shown to be effective in treatment of male breast cancer194, hormone
treatment has been shown to be potentially damaging to quality of life of premenopausal
women post treatment. For this reason, AIs are usually used in postmenopausal women
and men. The potential of drugs such as these should not be overlooked, as the ability to
treat cancer without cytotoxic drugs is one way of limiting the well-documented and
generally distasteful side effects of chemotherapy.

Continuing with the theme of non-cytotoxic drugs for the treatment of cancer leads to the
anti-angiogenesis agents.

These drugs attempt to combat tumor growth through an

indirect route, by depriving them of the vasculature necessary to grow, rather than by
inducing apoptosis. This inhibition is possible because cancers have been observed to be
incapable of growing beyond two millimeters in size without the production of a stable
vasculature195. With this in mind, bevacizumab was developed and first approved by the
United States Food and Drug Administration (US FDA) in 2004196. Bevacizumab is a
human monoclonal antibody which targets vascular endothelial growth factor (VEGF), a
factor which is largely responsible for the production of vascularization in the human
body197. VEGF is often over expressed in cancerous growths, as the goal of such growths
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is to replicate as quickly as possible; thus, combating the expression of this growth factor
can slow tumor progression198. Preventing the angiogenic shift from unvascularized 2-3
mm tumors to vascularized, metastasizing cancer can be critical to combating such a
growth, but action to stop such a progression must be taken early199. As early detection
abilities improve and increase the number of tumors which can be made visible, drugs
which can retard angiogenic growth and maintain tumors at manageable sizes will
become more and more valuable. Further, the various other effects of bevacizumab, such
as regeneration of normal vasculature and tumor oxygenation, occur in concert with the
effects of cytotoxic drugs, thus making bevacizumab ideal for adjuvant/combination
therapies200, 201. Furthermore, bevacizumab is well tolerated202, 203 and associated with
only mild or treatable side effects. The drug is even inexpensive as compared to other
chemotherapies204. However, despite all these positive attributes, bevacizumab is still
only truly effective in combating very early stage tumors. Anti-angiogenic research does
hold promise for future success in the clinic.

The other big name in the field of anti-angiogenesis is an old one, soiled through a
textbook example of poor pre-market testing. Thalidomide is a glutamic acid derivative
which was first synthesized in 1954205. The drug was immediately noted for being so
non-toxic that a lethal dose causing death of half an animal test group (LD50) could not be
established and the fast acting relief of myriad symptoms, including morning sickness206.
The drug was marketed over the next decade as a non-barbituate sedative, especially
popularly prescribed to pregnant women. However, thalidomide proved to be tetragenic

24

and over 10,000 babies were born with severe debilitating birth defects prior to the
discontinuation of the drug’s usage. From this negative story comes a silver lining of
good news, as thalidomide was not completely abandoned from research laboratories.
Over the next fifty years, a range of uses for the drug have been developed. Most
importantly to the oncologic community, it has been shown to be anti-angiogenic in
nature207. This characteristic, coupled with low toxicity, has led to experimental use
against a wide range of solid tumors208, and even FDA approval for cancers such as
multiple myeloma209. While being administered exclusively through oral tablets210, the
mechanism of action for thalidomide has yet to be elucidated fully, even after decades of
study211. What is known is that thalidomide is composed of a racemic mixture of two
enantio-isomers, which racemize rapidly under physiological conditions212.

This

attributes to the speedy effect of the drug, as well as the masked tetragenic effects, as
only one of the isomers is tetragenic and only in the racemized form. Also, the drug is
rapidly broken down in the body, with a half-life of only 4-5 hours. This point explains
the almost negligible toxicity of the drug, as chemical build-up in tissues and organs is
almost impossible on this short timeframe. All of these properties make thalidomide an
attractive choice for non-cytotoxic chemotherapy.

However, concerns raised by the

thalidomide failure half a century ago, must still be addressed before this drug will
become widely accepted.
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Tumor Microenvironment and Growth
After reviewing the major players in the field of chemotherapy today, the next logical
step is to examine the target for the drugs, i.e. the tumor and associated metastasis.
Clinically, much work has been performed, using tumor size reduction and associated
progression-free survival rates as the metrics by which cancer treatment “success” is
determined. While these metrics are the quantitative measurements with which treatment
should be concerned, research must keep in mind the reasons for this success as this line
of inquiry will inform new approaches and directions. Description and visualization of
the tumor microenvironment has taken a back seat to drug development and mechanism
elucidation in the past twenty years. Luckily however, researchers are beginning to direct
more attention to the how and why of cancer development, angiogenesis and growth.
This knowledge will allow more successful treatment of carcinomas in the long run,
ultimately boosting the most important metric, survival.

The first and most important item of note when examining the tumor microenvironment
is the diversity of the area. Human neoplasms contain a plethora of differentiating cells
in terms of function213. From this variation comes perhaps the most important facet of
knowledge related to the tumor microenvironment, that tumors exhibit heterogeneity in
terms of cell type214. While one school of thought advances that tumors originate from a
single, malformed cell, tumor cell differentiation occurs early in the growth process. This
process leads to a series of concurrent factors which either inhibit or encourage growth215.
The carcinoma grows outward, through stromal cells on the leading edge of the tumor.
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These cells in turn interact with the surrounding extracellular matrix (ECM).

The

complicated interactions between these fronts of cells are often the largest indicator of
either growth or stagnation of the tumor. Dr. Stephen Paget was the first to put forward
the “seed and soil” analogy216, in which he compared a neoplasm to that of a seed and the
surrounding ECM to the soil. By controlling the soil he postulated, one could retard the
growth of a seed. As any farmer knows, it is easier to salt the ground than explant a
series of seeds.

This analogy leads easily to the question of how the cancerous “soil” differs from normal
tissue.

Studies have been performed to answer this question and have identified

numerous differences between cancerous and non-cancerous cells216. Cancerous tissue
often exhibits low levels of pH as well as glucose, which is attributed to the rapid
replication of cells, indicative of a tumor.

Also, hypoxic conditions are almost

universally present at tumor sites. The hypoxia is due to the lack of a comprehensive
vasculature; the lack of oxygen contributes to the large number of mutations seen in
malignant tumors due to the disrupted replication of DNA. Also, tumor tissue exhibits
high levels of necrosis as cells struggle to survive in the hazardous conditions described.
Ironically, necrosis of cells at the core of solid tumors has been postulated216 to actually
catalyze outward growth of the tumor as macromolecules and nutrients are released
within the core of the growth and become available to the proliferating cells on the
leading edge.
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This process explains why the core of the tumor differs greatly from the outer palisade
cells217. This point is also highlighted by the difference in interstitial fluid pressure (IFP)
in the tumor. Due to the poorly vascularized nature of the core of the tumor, caused by
the vascular irregularities inherent in tumors, IFP rises. The rise in IFP, coupled with the
generally porous or “leaky” nature of tumor vasculature,218 makes drug delivery via
normal routes e.g. blood pathways, very difficult. Also, the cells in the outer region of
the tumor, close to the blood vessels have a higher rate of proliferation than those found
in the necrotic core219. The increased cell density in the outer region makes penetration
deep into the tumor very difficult. Finally, the last major difference between healthy and
cancerous tissue can be seen in the difference in temperature. Temperatures in cancerous
tissue can rise as high as 113°F (45°C) 219. This excess energy can be used to catalyze
intracellular processes and thus speed processes such as metabolism and mitosis.

These differences in microenvironment amount to a double edged sword. On one hand,
properties such as rise in temperature provide the ability to target cancerous tissue
specifically using technologies such as temperature-sensitive polymers. Conversely, the
tumor microenvironment can present one of the largest obstacles to chemotherapy in the
form of drug resistance. Drug resistance can be developed through mutations of cells
surviving treatment (occurring rapidly and spontaneously due to the hypoxic conditions)
or can reside inherently in the tumor prior to exposure (de novo resistance)

220

. An

example of such resistance can be seen in the production of excess glutathione in tumor
microenvironments resistant to cyclophosphamide, a cytotoxic drug inhibited by the
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presence of glutathione214. Tumor chemoresistance is the leading cause of failure of
chemotherapy, because even if a small portion of the heterogenic tumor is resistant to a
given drug, that portion has the ability to regenerate to the previous size or larger221.

The investigation and visualization of the tumor microenvironment is an area of ongoing
work in the realm of oncology. Probes such as fluorescent nanoparticles and quantum
dots have been used to visualize tumor structures and vasculature215. Tissue preparation
and immunohistochemical staining allow post-excision analysis. Immunhistochemistry is
often used to determine the microvessel density of a tumor, which is directly related to
angiogenesis222.

This assessment becomes necessary as the quantification of

angiogenesis is essential in determining the stage of the tumor and propensity to
metastasize223. In general, the more vascularized the tumor the more advanced the
growth and hence the more danger to the host224. Thus, visualization of the cells is
important and allows further investigation of solid tumors. This heterogeneity of tumors
and the surrounding microenvironment, once studied and fully understood, may provide a
series of targets for treatments to check the growth of cancers225.

A better understanding of the microenvironment will, in turn, lead to a better
understanding of the mechanisms by which tumors grow and better methods through
which to model tumor growth. Such models are important in tailoring treatments to
patients and predicting efficacy of such treatments. The mainstream of thinking for a
long period, prior to the turn of the century, was that every carcinoma was inherently
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different and there was little possibility of predicting the growth of such a tumor through
a universal mathematical model. However, in 2001, it was shown that tumors throughout
nature follow a same general exponential curve226. While simplistic (growth slows as it
reaches a limiting factor), this statement describes that cancer cells react as a population,
meaning that growth is not completely unchecked. This concept of tumor growth relates
directly with the discussion previously on tumor microenvironment, and raises the
interesting question of how medicine might force the retardation of growth sooner.

Development of mathematical models not only highlight questions such as how tumor
growth can be examined but allow the elucidation of better treatment regimens by
identifying key parameters, such as tumor size, vascularity location etc. This is achieved
first, much like any other mathematical model, by defining the relevant variables. Items
such as cell structure, environmental factors, adhesion between cells and rate of
proliferation are often common across different proposed models227.

Behind these

obvious variables are, however, the complex interactions which one must quantify. For
example, as a tumor grows into the surrounding ECM, the ECM structure is damaged and
broken.

During this destruction, nutrients and growth factors such as VEGF are

released228 which can then be used by the advancing stromal cells. Therefore, it can be
easily argued that this advancement catalyzes itself through a positive feedback loop.
The growth, along with the VEGF, will induce angiogenesis which will further speed
tumor growth. Hence, mathematical models can be useful in the identification of an
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acceleration point for tumor growth and therefore can be useful in the determination of
indicated treatment at the present state of the tumor229.

Tumor growth presents a problem to simple modeling because growth is a dual-stage
process230. The first stage is that of pre-vascularization. Here, the tumor grows to the
size to which it is limited by the limited capacity to provide nutrients to the core via in the
absence of a vascular network.

In this stage, a tumor can grow no larger than

approximately 2 millimeters. However, with angiogenesis and the ability to supply
necessary elements to other regions, growth commences again.

The second stage

progresses until metastasis occurs, at which point modeling becomes unwieldy and less
relevant. Thus any model must represent the growth as a dual compartment model231.
Therefore, the models can be described in terms of two stages, as outlined by Sachs231;
the first stage of tumor growth can be presented as such:

N is the number of clonogenic cells and λ is a constant231. This simple exponential
growth equation is adequate for modeling the first stage; however, upon angiogenesis,
two equations are needed. The first equation represents the tumor core:

K is a carrying capacity determined by the second compartment volume. The second
equation is related to the speed at which vascularization occurs, the depth at which it
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occurs and speed of replication resulting from such nutrient availability.

These

characteristics are represented by the general form:

D is the depth of penetration, S is the speed of penetration, V is the volume of the tumor
at time 0, and ρ is the density of cells in the tumor at time 0. This simplified model is
meant to describe the potential for the tumor to grow to a carrying capacity K, which is in
turn defined by the level of angiogenesis, as time progresses.

This mathematical

description again correlates to the idea of quantification of the stage of cancer relating to
that of the level of vascularization of the tumor.

This proposed model can obviously be improved through the inclusion of further
variables or the use of further compartments which have been proposed to represent
“shells” or areas of differing tumor growth232. The example model proposed is intended
to provide a preliminary understanding of the complex system that is tumor growth.
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CHAPTER TWO
TUMOR TREATMENT IN MODERN MEDICINE

Tumor Treatment and Administration Methods
The information provided to this point describes two of the tools required to treat cancer
using chemotherapy.

The first tool, the drugs themselves, is specific to a method,

whether it be deoxyribonucleic acid (DNA) intercalation, anti-angiogenesis, or any other
mechanism.

The second tool, knowledge of the physiology of tumors, guides the

selection of the drug. The missing tool is the method of drug administration to the tumor.
Modern chemotherapy administration comes in many different forms, the exact
mechanism is usually indicated by the location and stage of the cancer.

Intravenous (IV) chemotherapy was first used in 1942 at Yale University233. Following
this initial success, IV chemotherapy became the gold standard against which other
chemotherapy regimens were judged. IV chemotherapy seems logical at first glance; it is
easy to administer, compatible with most hydrophilic chemotherapy agents, poses a low
risk of infection, and exhibits a high rate of efficacy. This route of administration relies
on the circulatory system to route the drug through the entire body, exposing areas other
than the target tumor to the cytotoxic drug. However, recent studies have shown that, for
some solid tumors, intraperitoneal (IP) administration is as effective or even more
effective than a similar concentration administered through IV234, 235. IP administration
has been shown to be more cost effective in terms of cost versus survival-free
progression, making it an interesting economic choice236.
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Other studies have even

examined using the two together, to great effect237.

The one drawback of IP

administration appears to be slight toxicity to the injection site, as one would expect from
a higher, localized concentration of drug238.

Oral chemotherapy presents the most patient-compliant form of chemotherapy. Patients
are often more inclined to take a pill than undergo injections or infusions, and oral
chemotherapy does not require a visit to the physician’s office. However, only certain
drugs are capable of oral administration while others require modification, such as
encapsulation239. Even so, oral administration has been found wanting in terms of tumor
response when compared to standard IV administration240.

For this reason, oral

chemotherapy is often only used in cases where previous evidence assures success, or
when other methods have failed.

The newest iteration of administration is that of intratumoral (IT) injections. This method
consists of injecting the chemotherapy directly into the tumor. This has the advantages of
completely perfusing the tumor (allowing access of the drug to the poorly vascularized
core) and maximizing the drug concentration at the desired site. This method has already
been shown to be more effective than IV treatment in some cases, with reduced toxicity
allowing treatments of children and the elderly241. The reduced toxicity is attributed to
the lack of “collateral damage” as the cytotoxic drugs do not penetrate any tissues other
than the target and have perhaps very slight diffusion into the surrounding cells 242.
However, the largest obstacles to the acceptance of IT treatment stems from conservative
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physicians and the need for a clear, accessible tumor. Surgical removal often does not
leave a visible target and so IT treatment is currently regarded as a “pre-operative”
modality.

After determining how to administer chemotherapy, one must determine the timing.
Traditionally, chemotherapy is administered in high, concentrated doses with weeks in
between to allow the body to recover243. This “cool-down” period is necessary when
such high levels of drug are introduced because build-up of the cytotoxic drug not only
occurs at the tumor site, but also in collateral, healthy tissue. Because of this necessary
break in treatment, tumor cells have a chance to replicate and, worse, develop drug
resistance mechanisms.

Therefore it is imperative to find ways of administering

chemotherapy on a more frequent basis. This can be done through simple modification
of dosing schemes, such as through metronomic or dose-dense scheduling.

The goal of metronomic scheduling is to expose the tumor to a constant, frequent, low
level of drug244. Because of the low levels of drug administered, cytotoxic side effects
are seen less frequently, as the body is more capable of clearing the drug not absorbed
into the tumor and preventing the build-up of the drug in “healthy” tissue. Also, by
constantly exposing the cancerous growth to a given cytotoxic drug, the tumor has no
chance to regrow and has much less time in which to develop a drug resistance. Thus,
since most cytotoxic drugs attempt to interrupt cell division at a certain stage, it stands to
reason that it is essential that all the tumor cells be exposed to the drug while passing
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through that stage of the cell cycle. A sound idea in practice, low dose metronomic
(LDM) scheduling has been effective in a number of studies involving paclitaxel245, 246,
cyclophosphamide83, and anti-angiogenic factors247. Even more interesting, tumors that
develop resistance to LDM have been shown to still be sensitive to higher doses of drugs,
at least in the case of cyclophosphamide83.

The main difficulty with LDM is a poorly defined lower threshold for the therapeutic
window for most chemotherapeutics. That is, it is not clear at what level one can
administer the desired drug and still maintain efficacy. Dose-dense (DD) chemotherapy
evades that question, and encompasses a more constant schedule. The goal of DD is to
maintain a constant, high level of drug at the site of the tumor. This delivery is executed
in a similar manner as metronomic scheduling, with higher concentrated doses than LDM
but lower doses than traditional means. Thus, by continually replenishing the drug
concentration at the tumor site, better clinical results should follow. Success with this
treatment process has been seen with multiple paclitaxel/platinum62,
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and other

combination regimens248. The greatest problem with dose-dense chemotherapy is the
increased toxicity associated with the more frequent treatment administration. However,
even this problem has been shown to be controllable through conscientious dose choice61.
Thus, DD chemotherapy is becoming a more attractive option in hospitals and clinics
around the world.
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Biomaterials are increasingly playing a role in aiding the administration of
chemotherapeutics, and are being used as in situ delivery systems, microparticles, and
polymeric conjugates. A chemotherapeutic is often administered in a form other than a
free drug in an IV solution. The best example is a diluent such as BASF’s Cremophor
EL®. This excipient, which is simply a reaction of ethylene oxide and Castrol oil, is
used to solubilize the hydrophobic drug paclitaxel. This allows the administration of
paclitaxel through IV means into the circulatory system without massive precipitation of
the solute. The problem with such a system lies in the side effects elicited by the
inclusion of Cremophor EL, which are highlighted by hypertension. With the already
high level of harmful side effects seen in the use of chemotherapeutics, one can
understand why any further toxicity caused by additional components would be
undesirable.

Not all delivery aids are solubilizers and excipients. Pluronic® copolymers have been
shown to interact with tumors, independent of drug presence249. The presence of these
polymers at the tumor site has been shown to sensitize normally drug-resistant tumors.
The mechanism of action for this sensitization is proposed to be the adenosine
triphosphate depletion induced by the presence of the polymers, thus weakening the
cancerous cells defense mechanisms.

Hence the administration of these polymer

solutions concurrently with chemotherapeutics has shown promise in overcoming of
multi-drug resistance in tumors249.
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Polymers are valuable to chemotherapy as liquid carriers and polymer drug conjugates
are playing an increased role in therapies as well. Because the majority of the drug’s
target resides within the cell, usually either DNA or microtubules, transport and uptake to
the cytoplasm is a key component of cancer therapy.

Initially, viral vectors were

attempted to facilitate such transport. However, problems were seen with toxicity and
immunogenicity250 and so non-viral methods were explored.

This led to research

involving cationic polymers. Cationic polymers allow the conjugation of many different
anti-neoplastic drugs. These conjugates exhibit better biocompatibility, circulation time
and drug uptake within cancerous cells, while inflicting lower systemic cytotoxicity250.
Cationic polymers rely on the cell substructure to cleave the polymer from the drug,
hence catalyzing the prodrug to drug transition in situ.

Polymers are also tailored to be environment sensitive to release their drug payload.
Polymer drug conjugates have been designed both with pH and temperature sensitive
linkages. Polymers conjugated to drug through acid-sensitive linkages are capable of
circulating through the body multiple times until the cancer site is reached. Acidic pH is
indicative of a tumor site and so the polymer-drug conjugate will preferentially separate
at the tumor site251, thus allowing targeted delivery to the tumor microenvironment.
Temperature-sensitive polymers are capable of working in the same manner, though the
polymer-drug linkage is less likely to be a strict covalent bond and more likely a sol-gel
network252. These examples are just a few of the ways that the tumor microenvironment
can be targeted by polymeric conjugates.
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Through the use of polymeric linkages, delivery mediators can also be attached. Binding
the drug to a polymeric scaffold creates other sites for attachment. These sites can be
used to bind targeting moieties, such as folic acid. Folic acid constitutes an interesting
choice for a targeting element as it is easy to attach, upregulated in many tumors,
overexpressed in relation to size and grade of tumors, and normal tissues shield the
majority of their folate receptors253. Thus the complex will be preferentially incorporated
by cancerous cells and will release the drug from the prodrug complex within the desired
cells.
Polymeric conjugates are not the only option for
facilitated delivery to cancer cells.

Liposomes

(Figure 2.1) also offer a significant advantage over
free drug administration. Liposomes consist of a
lipid bilayer surrounding an inner cavity which,
through special processes such as water-in-oilFigure 2.1: Example
configuration of a liposome
(Source: www.thescientist.com)

water emulsion preparation, can be made to
encapsulate drug254. These liposomes then freely

circulate the body for extended periods of time, due to their relatively bioinert
characteristics, until they settle into tissue. The “leaky” vasculature of cancer tissue
allows the preferential deposition of liposomes at the tumor site. However, once in place,
the stable liposomes are not inclined to self-degrade and release the encapsulated drug.
Many mechanisms, such as phototriggering, have been investigated to allow the in situ
release of drug from liposomes255.
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As their name implies, liposomes are inherently hydrophobic, at least to a slight degree.
While useful for applications such as traversing the blood brain barrier, this characteristic
is detrimental in general systemic delivery. For this reason, liposomes can be surface
modified using a process described as PEGylation256. This process entails the attachment
of the biocompatible and hydrophilic polymer polyethylene glycol (PEG) to a given
structure to increase the overall hydrophilic and biocompatible nature of the entire
complex. The process, first described in the 1970’s, allows the attachment of PEG to a
bioactive molecule through various mechanisms such as acylation or methylation, etc.257.
This molecule does not have to be a polymeric complex, but can be a protein, peptide or,
even for chemotherapeutic applications, a hydrophobic anti-neoplastic drug.

Further work in the field revolves around the use of nanoparticles and microspheres. The
aim of such work is similar to that of liposomal delivery, but attempts have been made to
use less lipophilic carriers. These carriers generally take the form of nanoparticles or
microspheres.

These small particles can be prepared from a variety of materials,

polymeric and non-polymeric. Nanoparticles prepared from biodegradable polymers
such as polylactide-co-glycolide (PLG) are gaining favor currently as PLG has a low risk
of a toxicologic or immunogenic response.

These items can be prepared for drug

delivery and diagnostic uses for cancer therapy258. Nanoparticles will also preferentially
seek out the ‘leaky’ vasculature of tumors, much like liposomes. The leaky vasculature
provides an almost sieve-like system, leading to the surrounding tumor, in which a
properly sized nanoparticle will deposit259.
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Equally important to the retention of

nanoparticles in the tumor is the poor drainage of the vasculature relative to normal
tissue. These two factors combine to allow a majority of the administered nanoparticles
to eventually target the tissue. The collection of fluorescent nanoparticles in the tissue
can allow non-invasive visualization of neoplasms.

Nanoparticles and microspheres have already begun to show their worth in terms of drug
delivery. Studies as early as 1996 showed that microspheres containing methotrexate
elicited a better clinical response to treatment than free methotrexate260. Anti-angiogenic
delivery is quite popular and effective due to the area of effect261. Nanoparticles have
even found use in treating cancers of the central nervous system, where other methods are
only effective over a limited area262. Nanoparticles have also been shown to aid in
sensitizing tumors which were otherwise resistant to their payload drug, much like the
Pluronic® polymers263.

Work has also been conducted using microspheres as

placeholders for ligands, thus creating actively targeted therapies. These properties,
along with the ability to incorporate most drugs used in chemotherapy in a
pharmacologically active manner, make nanoparticles and microspheres a key tool in the
battle against cancer264-266.

While nanoparticles show promise in targeted therapy, the next step is localized delivery.
The advantages of localized delivery over normal systemic treatments include lower
systemic toxicity, more efficient usage of the drug, and better treatment outcomes. The
difficulty in this field is the ability to deliver a suitable delivery vehicle to the site of
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treatment.

Medical devices such as implantable chemotherapeutic wafers for brain

cancer have been tried with little success. However, devices which do show promise for
localized delivery are injectable in situ forming implants.

These implants begin the treatment cycle in a solution (sol) form. This solution is then
administered to the desired area of treatment through a syringe or port system. Once in
place, or in situ, the implant then converts to the gel form. This transition is often called
the sol-gel transition and the mechanism through which this change is effected is one of
the distinguishing factors between systems. The majority of injectable in situ-forming
systems fall into one of three categories: (1) crosslinking/network formers, (2)
thermogelling systems, and (3) self-assembling systems267.

The first group of such systems relies on the difference of the environment at the site to
induce cross-linking and thus the development of the desired construct. This difference
can either be an inherent physiochemical difference or an induced change. Examples of
induced changes include ultraviolet irradiation, temperature and pH modification268.
Once cross-linking is induced, networks are formed between chains (usually polymeric).
These networks then release their pharmaceutical payload in a controlled manner269. The
release of such molecules can be modulated by the level of cross-linking, the polymer
scaffold employed, and the method of cross-linking270.

The most popular polymer

matrices in this area are those of the pH-responsive type, often using the biocompatible
natural polymer chitosan268.

These in situ implants are capable of being delivered
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through physiological pH (7.4), remaining in the sol state, to weakly acidic (pH 6.8)
environments where the sol-gel transition occurs271. In this manner, the transition to a
“delivery state” can be contained to a pH usually located only in tumor sites. While
effective, these types of treatments do have drawbacks.

Cancer pH values are not

constant across tumors or even within a particular tumor. Also, once formed, hydrogels
produced through sol-gel transition tend to be weaker physically then other methods,
making stability an issue272. These drawbacks are significant, and much current work is
being geared toward overcoming these obstacles.

More popular among researchers are the
thermogelling in situ forming systems.
These systems are activated by elevated
temperatures and are characterized by their
lower

and

upper

critical

solution

temperatures (LCST and UCST).
Figure 2.2: Example of a
thermogelling system280

The

commercially available family of Pluronic®
polymers is the best known example of such

a system273. These polymers are poly(ethylene oxide) and poly(propylene oxide) block
copolymers which allow the thermocontrolled construction of controlled delivery
implants by engineering the UCST to be between room temperature (~20ºC) and body
temperature (37ºC). When implants from polymers such as those described have been
formed in situ, controlled release of multiple chemotherapeutics has been exhibited274,275.
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Systems engineered using polymers such as elastin-like polypeptides can even be
designed to deliver multiple drugs at different temperatures by creating regions with
different CSTs276. The flexibility of such systems is attractive to researchers, but the
reliance on physiologically fluctuating temperature again poses a hindrance to
widespread use.

The final group of in situ-forming implants is perhaps the most complicated, yet
intriguing, group. This group relies on the self-assembly of implants once introduced to
the site. This reliance on mechanisms other than cross-linking, pH, or temperature makes
systems such as these more difficult to prepare but more useful once in place. These
systems often rely on precipitation and phase-separations to elicit the desired construct.
Collagen gels have been shown to be capable of intratumoral delivery using such an
approach277. Other materials involved in systems using methods such as these include
novel tissue adhesives278 and hyperbranched hydrogels279 which are designed to be
physically more stable and therefore more effective drug delivery systems than those that
rely on external stimuli to induce the sol-gel transition.

Extension – What Next?
The obvious question for one to ask is “what next”? A significant base of work has been
put into understanding chemotherapy. The drugs with which chemotherapy is performed
are well documented. Current understanding of the tumor microenvironment and kinetics
of growth are becoming better understood at a rapid pace with today’s technology.
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Delivery routes other than traditional IV administration are becoming more common and
accepted.

Chemotherapy has the potential to become a much more prominent player

in the war on cancer. Through more effective usage and administration of common
chemotherapeutics, chemotherapy can be made into a more acceptable treatment for
cancer patients. The goal of such optimization should revolve around limiting side
effects and increasing the efficiency of such treatment.

Ovarian cancer is a known chemoresponsive malady.

Treatment of this disease

commonly focuses around usage of paclitaxel and platinum-based drugs administered
intravenously in combination therapy. This treatment regimen has been shown to aid in
the regression of tumors following surgical debridement. This treatment is not, however,
without drawbacks; systemic IV administration leads to full-body toxicity and a slew of
undesired side effects. Also, drug is inefficiently delivered to the tumor, and even less
reaches the intracellular environment where anti-neoplastic activity can occur.

Furthermore, this uncontrolled delivery to the tumor site causes the discarding of the
traditional clinical tool, the therapeutic window. The therapeutic window is often defined
as the concentrations of a bioactive agent above the lowest efficacious dose but below the
maximum tolerated dose. Work such as the development of dose dense and metronomic
scheduling has contributed greatly to allow controlled drug levels, but still does not
account for a truly controllable drug concentration.

Also, each time agents are

administered, excipients such as Cremophor EL® are required for treatment. These
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agents themselves have been shown to elicit harmful side effects when administered
systemically. The administration of controlled delivery vehicles also must ensure the
biocompatible nature of the device, and the eventual need for clearance or removal from
the body.

Treatment must be optimized; this optimization can take the form of an in situ- forming,
biocompatible construct. The injectable nature and self assembly of such a device allows
localized delivery of chemotherapeutics. Administered intratumorally, such an implant
will remove many of the issues resulting from systemic administration of drugs. Also,
through the use of a biocompatible, absorbable system, safety can be increased and
explantation will never be required.

Lastly, through the controlled diffusive release of encapsulated drugs, such as paclitaxel
and carboplatin, treatments can be optimized to provide constant levels of drug. Dose
dense and metronomic dosing schemes have already shown that lower levels of drug
administered more often can be effective. It therefore stands to reason that a constant
delivery of low levels of drug in situ could be even more effective, again limiting
systemic toxicity.

With all of these factors considered, an injectable in situ forming implant is therefore
proposed. This implant should be biocompatible and capable of controlled release of
chemotherapeutics. By using cancer of the ovaries as a model, an effective system could
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be developed. Once proven, the developed system could in turn act as a model for
development of other treatments for chemosensitive cancers at other sites in the body.
Using new polymeric systems, this treatment could open up new, safer, and more
efficient pathways for patients stricken with cancer.
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CHAPTER THREE
THE OC SYSTEM: A METHOD FOR LOCALIZED SUSTAINED DELIVERY
Overview
As noted in the previous chapter, there is currently a dearth of technology specifically
engineered to encompass both local and sustained delivery. If such a candidate could be
designed and prepared, a significant step in the war on cancer would be achieved. One
such delivery system being developed is the OC system (Poly-Med, Inc., Anderson, SC).
This platform technology comprises an injectable in situ forming drug delivery depot that
does not rely on fluctuating environmental factors to induce the sol-gel transition.
Rather, the mechanism of formation is simply exposure of the formulation to an aqueous
environment. The injectable solution is composed of several components. The OC
polymer forms the actual depot delivery system. OC polymers are a block copolymer
design with both hydrophobic and hydrophilic segments.

In order to facilitate the

injection of the system, a polymeric diluent is used. If necessary to further modulate
release, polymeric additives are introduced which control the structure of the delivery
construct and construct drug interactions. The final component of such a system is the
bioactive agent, such as carboplatin, which is used for delivery.

This system is a

homogenous solution prior to introduction into a biological environment. Upon injection
into the desired site, a drug delivery depot forms rapidly (Figure 3.1).

This depot formation occurs when the water-miscible polymeric diluent evacuates the
solution, allowing the remaining solutes to coalesce. Following this theory, the OC
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polymer orients itself into a thermodynamically favorable conformation, resulting in a
stable polymeric construct. The uniqueness of this formation in relation to other hydroset
gels is exhibited by the hydrophobic and hydrophilic differences throughout the polymer
chain. This property difference, inherent in the polymer chain itself, helps drive the
orientation of the delivery depot to a repeatable, stable conformation. The inclusion of
polymeric additives can be used to further control the structure, and thus the release
properties, of the construct.

The included bioactive agent is evenly distributed

throughout the construct. Delivery of the drug is then controlled through a diffusionmediated release which is dependent on the surface area of the implant exposed to
aqueous environment (blood and living tissue).

Figure 3.1: Theoretical mechanistic diagram of OC system introduction into an
aqueous environment. Red indicates the hydrophobic domain of the polymer. Orange
indicates the hydrophilic domain of the polymer. Green indicates the hydrophilic
diluent. Blue indicates the aqueous environment. Source: “Intravaginal Drug
Delivery” in Polymers for Vascular and Urogenital Applications (S.W. Shalaby,
K.J.L. Burg, W.S. Shalaby, eds.) J. M. Olbrich, W.S. Shalaby, G.H. Hilas. Taylor &
Francis Group, LLC (2012)
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Upon exposure, the hydrophobic portions of the copolymer chain orient themselves to an
inner core, while the hydrophilic portions form the outer regions of the delivery depot.
Following this orientation, a multi-layered construct is developed through which release
of the drug payload, homogenously distributed within, is achieved by diffusive release.
This diffusion can then be modulated through modifications to either the hydrophobic or
hydrophilic segments of the chains.

The novelty of this platform technology lies in the ability to modulate nearly any of the
variables. Release speed, degradation period, and even gel formation speed can be
tailored to the exact needs of the individual application through manipulation of the
described portions of the system. The major portions of such a system are discussed
more thoroughly subsequently.

Polymers
The OCs are novel polymers capable of sustained controlled release of a pharmaceutical
payload in the presence of an aqueous environment77,78,79. These polymers are prepared
through a bulk, ring-opening, multi-step polymerization of monomers and short chain
polymers including lactide, glycolide, trimethylene carbonate, diisocyanate and
polyethylene glycol, depending on the intended application. An example of the OC
family is OC9. The polymer is composed of polyethylene glycol (PEG; Mw=400) and
DL-lactide/glycolide (80/20) blocks. The initial step in the polymerization of such an
agent involves extensive drying of PEG 400, which serves as the initiator, under vacuum
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in a reaction flask. The metallic based catalyst is then added to the flask. To construct the
prepolymer, cyclic monomers (DL-Lactide (DLac) and glycolide (Gly)) are added. Ringopening of the cyclic monomers and chain growth of the polymer occurs.

Block

structures of PEG and the absorbable monomers, respectively, are prepared.
Polymerization is allowed to proceed under elevated temperature to completion.
Completion is monitored through gel permeation chromatography (GPC) analysis of
molecular weight. Once the prepolymer has been prepared, the second polymerization is
initiated. This step is performed by the addition of diisocyanatohexane (diiso) to the
reaction flask. The polymer is then catalyzed with heat to allow the linkage of the diiso
units to the prepolymer. Following the completion of polymerization, purification is
performed on the product to remove impurities and unreacted monomer. Purification is
executed through the dissolution of the full contents of the reaction flask in
tetrahydrofuran (THF). Once the contents of the flask have been solubilized, a small
amount of isopropyl alcohol (IPA) is added to ensure that free diiso groups have been
neutralized. The solution is then poured into a chilled aqueous non-solvent to precipitate
the desired polymer. Polymer is subsequently dried on Teflon® sheets under low heat
and vacuum. This seven step process is outlined in Table 3.1.
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Table 3.1: The OC Polymerization: A General Procedure
Step

Description

Chemical Example

Diol is dried in a flask
1

under vacuum. This
serves as the initiator.

Heavy metal compound
2
is added as the catalyst.

Cyclic monomers are
added for the pre3

polymerization. A ringopening bulk reaction
occurs.
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Chain extending agent is
added after the pre4

polymerization.
Polymerization, chainextension, occurs.
Organic solvent is added
to the polymer to allow

5
purification through
precipitation.

Isopropanol is added to
6

neutralize free floating
chain extending agents.

The entire solution is
7

then poured into ice

H2O

water (H2O). Resulting
polymer is collected.
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The result of such work is an absorbable block polyether-ester-urethane (PEEU) or
polyether-ester-carbonate-urethane (PEECU) copolymer (the latter if trimethylene
carbonate is used). These polymer structures are amphiphilic in nature, containing both
hydrophobic and hydrophilic segments joined with flexible urethane linkages
(contributed by the diisocyanate linkages). Polymeric properties have been manipulated
by changing the monomeric composition and order/structure. The amphiphilic state of
such polymers allows the unique formation of a polymeric construct when the polymer is
exposed to water. The hydrophobic portions, contributed by the lactide and glycolide
blocks, of the polymer orient to the inner core of the polymer while the hydrophilic
portions, contributed by the PEG blocks, are presented to the aqueous environment. The
inclusion of the urethane portions allows the polymer to reach this thermodynamically
favorable conformation at an unparalleled speed. This rapid (fully complete in less than 3
minutes) formation allows circumvention of the normal “burst” effect in delivery of a
pharmaceutical which usually plagues such technologies. This gelation was quantified
using an Anton-Parr Rheometer (Physica MCR 301). The rheological analysis of one
such precipitation is depicted in Figure 3.2.
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Figure 3.2: Complex viscosity over time for gelation of OC polymer and organic
solvent
Due to the rapidity of gelation, little (<5%) drug is lost during evacuation of the diluent
and bolus formation. Thus, this series of polymers has unique properties not previously
explored. These polymers are constructed from generally well characterized and safe
monomers used in many materials and devices already on the market which should allow
Food and Drug Administration acceptance and eventual marketing.

Preliminary

cytotoxicity data has been gathered on a majority of the samples, resulting in scores of ‘0’
according to International Organization for Standardization (ISO) 10993-5 testing. This is
the best score possible on the ISO scale and analogous to a rubber stopper control test.
The properties of the example OC polymer, OC9, can be seen in Table 3.2.
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Table 3.2: Pertinent Properties of OC9 Lot 1 Purified
Property

OC9 Lot 1 Purified Values

Composition

PEG400 // DL Lactide/Glycolide

Prepolymer to diiso molar ratio

1 to 0.8

Number average molar mass (Mn)

10,240 Da

Weight average molar mass (Mw)

18,566 Da

Polydispersity index (PDI)

1.81

Differential scanning calorimetry
(DSC)

No thermal events between 25 and 260 °C

Mass loss at 6 weeks

17.6 %

Mass loss at 9 weeks

55.4 %

Composition and pre-polymer ratio were calculated using monomer values. Molecular
weights and PDI were gathered from GPC analysis on a Waters GPC system using a four
column set-up consisting of Styragel® 7.8 x 300 mm columns using dichloromethane as
the mobile phase. DSC was performed on a Perkin Elmer DSC 6 with a heat scheme of
20-300°C and a heating rate of 20°C/minute. Mass loss studies were conducted in vitro
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using laboratory balances, over a period of 4-12 weeks depending on polymer, with
storage at 37°C in presence of phosphate buffer (physiological pH 7-7.5).

From this data, many important facets of the OC polymer can be seen. First, the system
is degradable in vitro, as is evidenced by 55% mass loss after 9 weeks. However, the
majority of the construct will still likely be present after 6 weeks, allowing a window of
controlled delivery.

It is also interesting that the degradation process appears to

accelerate, which stands to reason as such a process is often self-catalyzing due to
degradation byproducts and the increasing local acidity of the construct. The PDI
indicates that a rather wide range of polymer chain lengths are produced, showing the
polymer does exhibit some heterogeneity. Furthermore, the lack of thermal events
reported by the DSC indicates that the polymer produced is amorphous. This likely aids
in the miscibility of the polymer with the diluent.

Diluent
The OC gels alone are too viscous for easy application into the body through most
normal methods. Accordingly, a method of dilution was developed for these samples that
allows delivery through a standard Leur-lok® needle and syringe. This ability entails the
dissolution of the OC polymer in a water-miscible polymeric diluent such as PEG. Once
dissolved, the polymer is injectable. The water-miscible diluent then evacuates into the
surrounding environment, precipitating the other solubilized components and allowing
gelation of the desired depot. Low molecular weight PEGs such as 200, 400 and 600 Da
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are used for this solubilizing purpose as the PEG itself must be a non-viscous liquid at
room temperature. PEG has been shown to be biocompatible and does not elicit a
dramatic/malignant immune response upon injection into human tissue.

Experimentation into modification of PEG to aid delivery has also been investigated.
The purpose of end-group modification is to make slight changes to the polymer-diluent
interaction. The two major modification schemes used in this work are acetylation and
succinylation. These processes in general involve the introduction of a functional group
compound, succinic anhydride in the case of succinylation, into an organic solvent at a
low weight percentage. The solution is then heated and stirred mechanically to dissolve
the compound. Once the compound is dissolved, PEG 400 is added to the flask. The
temperature is increased and the reaction stirred for an extended period of time. After
cooling to room temperature, the contents are poured into centrifuge tubes and the flask is
rinsed with organic solvent to collect as much of the polymer as possible. The product is
centrifuged and the organic solvent supernatant is decanted. Acetone is added to the
tubes and then sonicated to break up the centrifuged pellet. Finally, the polymer is placed
under a hood for air drying before being placed in a vacuum oven at room temperature
overnight.

In the case of PEG, a diol which possesses terminal hydroxyl groups,

acetylation was employed to create acetylated PEG 400 (denoted as G4A). This polymer
was shown through acid number testing to have converted terminal groups to acetyl
groups, while still maintaining the desirable viscosity of stock PEG. G4A was used
throughout the project as an experimental alternative to stock PEG 400.
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Additives
Polymeric additives are used to control
the formation of the construct. These
polymers can serve in myriad ways,
depending on the given needs of a
certain application. They can be used
to increase the overall hydrophilicity of
a construct and thus slow release.
Figure 3.3: Theoretical demonstration of
mechanism of large molecular weight
additive interaction with depot formation.
Purple circle indicates additive.

Conversely,
molecular

they
weight

can
or

be

large

branched

structures that allow perfusion of water into the delivery construct, which in turn
increases the area for diffusion and thus the overall rate of delivery (Figure 3.3). Beyond
this simple additive formation manipulation, charged additives can be used to induce
drug/additive interactions which, in effect, produce hybridized drug/polymer salts. Work
has gone into determination of additive and polymer pairings which yield desired
characteristics. These delivery systems range from 3 day rapid delivery to linear release
over a period of weeks capabilities, and can be tailored to specific applications in
conjunction with myriad drugs.

59

Injectability Checks
The proposed system is intended to be capable of localized injection.

The major

objective of the diluent portion of the system is to solubilize the OC polymer. The OC
polymer itself has been designed to allow superior precipitation mechanics. Diluent has
been included in other precipitation systems as mentioned in Chapter 2; however, these
systems generally require large amounts of diluent for solubilizing the chosen polymer.
Because of this, as the mainly solvent system precipitates from the polymer, it generally
carries a large portion of the pharmaceutical payload from the delivery construct. This is
a major cause of the well-documented “burst-effect”. To this end, the OC system should
be deliverable through an 18 gauge needle with the minimum amount of diluent required
for room temperature delivery. This point was tested with a number of OC polymers as
well as non-OC polymer controls, with G4A diluent at diluent weight percentages of 40,
33, and 20%.

This testing was conducted with BD Precision Glide Needles (size

18G1½”) and 1 milliliter BD Leur-Loktm syringes. The results of this testing can be seen
in Table 3.3 with “Passing” being defined as system being capable of moving through the
18 gauge needle with reasonable force.
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Table 3.3: Injectability of Multiple Polymers in Differing Diluent Percentages
Polymer

Description
Non-urethane-linked
Controls
polylactide-coglycolides
Higher Mw OC using
OC16
a higher Mw PEG
prepolymer, slightly
crystalline
Similar to OC16 with
OC12
less PEG content
OC9
Base Polymer,
amorphous
Similar to OC9, with
OC4
higher PEG content
to encourage better
flow
OC4-S

Succinylated OC4

40 wt% G4A

33 wt% G4A

20 wt% G4A

Does Not Pass

Does Not Pass

Does Not
Pass

Passes at Room
Temperature

Passes at 50°C

Does Not
Pass

Passes at 50°C

Does Not Pass

Passes at Room
Temperature

Passes at Room
Temperature

Does Not
Pass
Passes at
37°C

Passes at Room
Temperature

Passes at Room
Temperature

Passes at
37°C

Passes at Room
Temperature

Passes at Room
Temperature

Passes at
Room
Temperature

From this data, many conclusions can be reached. First, the inclusion of the urethane
linkage and PEG segments in the OC polymers does encourage solubility and flow when
combined with a PEG based diluent. This can be seen when comparing any of the OC
polymers to the non-urethane-linked or PEG containing controls. Secondly, as expected,
the amorphous nature of the OC polymers is also a positive influence in regard to this
goal.

The more amorphous OCs passed more easily when compared to the semi-

crystalline OC16 and OC12, which passed more easily in turn than the even more
crystalline non-OC polymers. Interestingly, a higher PEG content in the base polymer
had effect in one instance (OC4 vs. OC9) while not in the more crystalline instance
(OC16 vs. OC12). This can possibly be attributed to a limitation of the experimental setup as the observations are strictly qualitative and therefore the resolution of differences
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between materials is limited by human observation. The final observation of note is the
fact that succinylation does not make OC4 more difficult to inject, but rather appears to
increase the injectability of the system. This can likely be to the inclusion of extra
oxygen groups on the base polymer, increasing the affinity of the base polymer to the
heavily oxygenated PEG. With this information in mind it can be concluded that OC9 in
a 67/33 weight percent mixture can be injected through an 18 gauge needle in a room
temperature setting.

Strengths of Such a System
With injectability determined, the described system can be used for intratumoral
perfusion of solid tumors, transarterial chemoembolization treatment of eligible cancers,
and systemic administration of the desired bioactive agent. The area most likely for use
of such disruptive technology is localized chemotherapy delivery.

Such a system,

assuming controlled delivery, has many advantages over other drug delivery mechanisms
such as microspheres and thermogelling polymers with regard to such therapy. These
include but are not limited to:


Reduced systemic toxicity due to the local delivery of such a system



Higher concentration of the drug at the desired site



Efficient use of drug through near complete (e.g. ~100%) delivery from
constructs and minimal loss in formation



Lower daily drug requirements due to increased efficiency
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Continuous exposure of drug to target site, reducing the ability of the tumor to
regrow or develop resistance



Perfusion of the tumor and delivery to the entire malignancy



Negation of the burst effect to allow targeting of a specific therapeutic window



Independence from oscillating physiological conditions such as temperature of
tumor environment for formation and delivery

With these advantages in mind, drug delivery from this system will be investigated to
determine the feasibility of using such a system in treatment of solid tumors requiring
constant exposure of chemotherapy. The goal of release should be a semi-linear firstorder release of drug to allow constant controlled exposure to the tumor of the
pharmaceutical payload. The release of this OC system is explored and discussed in
detail in Chapter 4.
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CHAPTER FOUR
DELIVERY OF MODEL HYDROPHILIC DRUG AND EVALUATION OF
VARIABLES THEREIN
Introduction
In continuation of the description and evaluation of the system that began in Chapter 3,
release was evaluated with respect to multiple variables within the OC delivery system.
In each of the following studies, doxycycline hyclate (DOX) was used as a model drug.
DOX is a well characterized and readily available hydrophilic drug used to treat myriad
conditions in the clinic at a relatively low cost. Doxycycline’s cost-effective nature
allows a large screening process to pinpoint potential studies to undertake with the much
more expensive platinum drug carboplatin (CAR). CAR and DOX are both similar in
hydrophilic nature and similar in molecular weight, furthering the argument for use of
DOX as a model drug. Finally, DOX release will be useful for potential indications
where large scale broad spectrum antibiotic use may be of benefit, such as treatment of
osteomyelitis or bacterial overgrowth in the gut or female reproductive tract.

DOX is also an excellent model drug as it is easy to assay with reverse phase highperformance liquid chromatography (RP-HPLC). This positive attribute can be attributed
to the hydrophilic nature of the drug as well as the presence of the multiple chromophors
present in the molecule. The benzene structures impart much of the resonance to allow
HPLC Ultraviolet detection; therefore, an HPLC method was developed for detection of
doxycycline in phosphate buffer. This analysis was conducted using a Waters (Milford,
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Massachusetts, USA) HPLC system. This system is composed of a 717+ Autosampler
connected to a 1525 Binary HPLC pump. Analysis was performed with the integrated
2966 photodiode array detector system (see Chapter 5 for more detail on HPLC and the
HPLC system).

Water’s Empower software and an in-line degasser were used to

supplement this arrangement.

The mobile phases for such analysis were ultrapure water and acetonitrile (ACN), both
doped with 0.1% trifluoroacetic acid (TFA). A Waters® reverse phase C18 column was
used to separate the drug from the mobile phases. The optimum method for doxycycline
detection with the described system incorporated a gradient method, as described in
Table 4.1. All samples were examined with at least a 10 minute equilibration step prior
to analysis to ensure method accuracy.

This analysis yielded a well-defined

chromatogram, as seen in Figure 4.1.

Table 4.1: Optimized Gradient HPLC Method for Detection of Doxycycline
Parameter

Value

Initial Mobile Phase Composition

77% Water/23% ACN

Final Mobile Phase Composition

62% Water/38% ACN

Run Time

10 minutes

Flow Rate

1 mL/minute

Approximate Retention Time

9.3 minutes

Detection Lambda (λ)

350 nm
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Figure 4.1: Example chromatogram of doxycycline HPLC run

Accurate and repeatable analysis of doxycycline allowed the preparation of multiple
standard curves.

Standard curves were developed from HPLC analysis of known

concentrations of doxycycline. Standard curves were always found to be linear with an
R2 value of greater than 0.995. The linear coefficients (slopes) of the curves were then
used to analyze the unknown results from the experimental runs. An example of a
standard curve obtained can be seen in Figure 4.2.
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Figure 4.2: Example of doxycycline standard curves utilized throughout study

The development of robust standard curves allowed the progression of the project to in
vitro release studies. Standard curves were generated monthly to ensure accurate analysis
of data. With the drug described and analytical ability ensured, the following general
method was used to evaluate the difference in drug release. After mixing the components
for the desired system, the drug-loaded polymer was evenly distributed into three glass 25
ml vials with approximately 1 gram of delivery system. Gel was then allowed to flow out
over several hours, to occupy the bottom surface of the vial to allow a reproducible
starting surface area for each test. Once the gel evenly coated the bottom of the vial, 10
milliliters of phosphate buffer (pH 7.2) was added to each vial. The samples were then
incubated at 37 °C, with gentle gyration, to simulate physiological conditions. At each
time period, the buffer was removed from each sample, filtered through an Acrodisc®
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0.45 µm filter to remove any insolubles, such as polymer degradation products, and
analyzed by HPLC. The results of this analysis were compared with those of the standard
curve to allow quantification of drug release from the samples. Using DOX as a model
drug, multiple delivery systems were screened for effect on drug release.

Liquid OC Comparison
The OC polymers can be divided into two different groups, the liquid and the solid OCs.
The distinguishing feature between the two types is the presence or absence of crystalline
regions within the polymer orientation. The liquid OCs (OC2 through OC10) are the
more amorphous of the two groups, and tend to be more easily injected than the
crystalline OC11-OC16. In order to examine the effect on drug delivery from the liquid
OCs, drug release from OC2 through OC10 was tested. The results of this testing is
presented in Figure 4.3 on the next page.
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Figure 4.3: Doxycycline release from the liquid OC polymers (n=3)
Note: Error bars omitted for clarity.

From this information it can be seen that OC9 and, to a lesser extent, OC2 appear to be
superior in regard to sustained release of the model drug doxycycline. Many conclusions
can be drawn from these results. These polymers all have similar hydrophilic PEG
regions and the associated polyurethane regions. The difference between these polymers
lies within the composition of the hydrophobic (e.g. non-PEG) block. First, OC5, 6, 7,
and 8 all incorporate the monomer trimethylene carbonate (TMC) in the hydrophobic
region.

Despite changing percentages and combinations with lactide and glycolide,

similar result profiles are seen. From this information, TMC-containing OC polymers do
not readily appear promising for the desired release profile.

OC4 and OC3 are similar in chemical structure to OC2, but possess a weight average
molecular weight half that of OC2.

These polymers consist of a lactide/glycolide
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hydrophobic block which exhibits promise in controlled release.

As is often

hypothesized in the area of controlled release, a higher weight average molar mass (Mw)
polymer allows increased retention of the pharmaceutical payload. The increased Mw
OC2 exhibits a reduced burst effect as well as closer to zero order release of the
subsequent drug. OC10 is also similar in composition to OC3 and OC4, but uses Llactide rather than DL-lactide. This change in lactide monomer conformation does not
have a large effect on drug release from these polymers.

OC9 has the most markedly different release profile within this experimental group. OC9
differs from the other liquid OCs in the base polymer composition percentage of PEG.
OC9 has a smaller hydrophilic portion than the other OC polymers. This reduction of
hydrophilicity, while allowing the hypothesized phase separation gelation, appears to
help controlled delivery. This can be attributed to the concept that DOX, a hydrophilic
drug, will preferentially diffuse through the hydrophilic domains of the release construct.
By limiting these domains, and thus the surface area of the hydrophilic areas, drug release
will be inhibited. The behavior of OC9 lends credence to this idea, i.e. the greatly
reduced initial release and greater control as compared to the other OC release profiles.

No polymer system tested exhibited greater drug release than 60% of payload initially,
and each had quantifiable release for subsequent days. This result suggests that the
system is effectively encapsulating drug in all instances and releasing at least a portion of
the administered drug in a controlled manner. Also, it is evident that at day 13, the date
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of termination for these studies, there is not 100% release of the hypothesized payload.
This payload is calculated based on the drug percentage of the original polymer
preparation and the amount of gel administered in each test sample. In order to more
fully understand the system, a better accounting of drug would be helpful. To this end,
an extraction method was designed.

The extraction method entails the application of 5 milliliters of acetonitrile (ACN)
following the completion of the release testing, which in this case is following day 13.
The ACN dissolved the polymer matrix and thus releases the remaining captured drug
into solution. The polymer/ACN mixture is allowed to shake at room temperature until
the polymer solid is no longer apparent in the release vial. This mixture is then combined
with 5 milliliters of HPLC grade water to create a bi-phasic mixture. At this point the
mixture becomes a cloudy liquid, as the polymer behaves as would be expected and
preferentially separates from the aqueous portion of the mixture, theoretically leaving the
majority of the hydrophilic drug in the aqueous portion. To further this separation, the
mixture is centrifuged at 13000 RPM for 10 minutes. The resultant supernatant is then
removed from the centrifuge vials and is thus finally devoid of the higher molecular
weight polymer precipitate remaining in the centrifuge vial. This supernatant, clear and
theoretically aqueous with solubilized drug, is then filtered and analyzed through HPLC.
This method was tested with a known drug value and was evaluated to have a 90%
extraction efficiency which was deemed adequate by team decision for evaluation of
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these OC systems. Each of the liquid OC release systems was tested using this extraction
technique, and the results of this analysis can be seen in Table 4.2.
Table 4.2: Partial Mass Balance Evaluation of Drug Release from the Liquid OC
Systems
% Drug
OC
% Drug Found in
% Drug Released at Day 13
Unaccounted
System
Extraction
For
2

82.5

5.5

12

3

84.5

0

16.5

4

85

0

15

5

73

1

26

6

76

2

22

7

81

1

17

8

78

2

20

9

58

35

7

10

80

2

18

As can be seen from this table, OC9 is the only polymer with a large amount of drug
remaining within the delivery construct following Day 13. In the cases of the other
release profiles, the extraction results allow a reasonable degree of certainty that release
has reached a completion. Also, the extractions allow a mass balance showing that, in
most cases, approximately 80% of the theoretically included drug is accounted for.
While not optimal, it is important to note that the extraction methodology is not 100%
efficient and that there are many opportunities for drug to be lost throughout the release
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study process. Thus, the results of these studies suggest that the OC9 system is the most
promising of the liquid OCs in terms of attaining a semi-linear release profile.

Solid OC Release Profiles
Following testing of the liquid OCs, polymers from the solid OCs were tested. These
polymers have larger hydrophobic block components, have higher molecular weight PEG
components in the hydrophilic domains, and have higher Mw values than the liquid OCs.
These polymers tend to gel into harder constructs but are difficult to administer through
the desired injection system, as described in Chapter 3. These polymers were tested in
the described release format and the results of this testing can be seen in Figure 4.4.

Figure 4.4: Release profiles of the solid OC polymers (n=3)
Error bars omitted for clarity
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From this data it is evident that the solid OC polymers do not have the same aptitude for
controlled release that the liquid OC polymers have. The large hydrophobic component
of these polymers, combined with the crystalline behavior inherent to such design, likely
inhibits the encapsulation/depot formation seen in the liquid OCs. Also, the higher Mw
PEG components of the hydrophilic domains also provide less “flexibility” than the lower
Mw sub blocks used in the liquid OCs. From this less favorable data, the decision was
made to move forward with the liquid OCs for future testing.

Additive Use – A6
Throughout the development of controlled release technology, much effort has been put
toward the use of additives to further control the release from a construct. In this regard,
four different additive groups were explored in relation to DOX release from the OC
system. The first additive investigated was A6. This polymer is low molecular weight
acid terminated polyglycolide. This polymer was included in polymer delivery systems at
5 and 10 weight percent loadings. The effect on release of DOX was quantified using
OC2, OC4, OC6 and OC9. The results of this testing are shown in Figures 4.5, 4.6, 4.7,
and 4.8 on the following pages.
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Figure 4.5: Effect of doxycycline release from OC2 system and the effect of A6
inclusion (n=3, error bars indicate 1 standard deviation)
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Figure 4.6: Effect of doxycycline release from OC4 system and the effect of A6
inclusion (n=3, error bars indicate 1 standard deviation)
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Figure 4.7: Effect of doxycycline release from OC6 system and the effect of A6
inclusion (n=3, error bars indicate 1 standard deviation)
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Figure 4.8: Effect of doxycycline release from OC9 system and the effect of A6
inclusion (n=3, error bars indicate 1 standard deviation)
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The results from this testing support the idea that polyglycolide (PG) microparticles can
impact release. In each instance, better defined in the OC6 and OC9 test batteries, A6
allows slow release from the constructs and encourages a more linear release profile.
OC9 shows that A6 is predictably capable of influencing release as the amount of the
additive in the composition increases. Greater than 10 weight percent A6 compositions
were not tested as these compositions proved difficult to inject and therefore would not
be viable clinically.

While these results do show that A6 can be used to control drug release, the mechanism
through which this is affected is not perfectly clear. There are two potential theories for
the way that A6 causes these changes. The first involves the effect that A6 has on the
depot formation. A6 is a large element in comparison to the flexible OC polymers. The
presence of these microparticles could cause disruptions in the formation of the typical
polymer depot structure, again affecting the hydrophilic delivery domains. Also it stands
to reason A6’s surface will protonate in the presence of an aqueous environment,
allowing stronger binding to both the positively charged doxycycline and the OC matrix.
This is supported by the fact that, as A6 quantities are increased, release is further
decreased, indicating that the A6 is potentially limiting this delivery/diffusive surface
area further.

A second theory involves a potential drug interaction between A6 and doxycycline
hyclate. Doxycycline hyclate is a salt, like most common antibiotics, composed of the
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doxycycline freebase drug and the hyclate combination of hydrochloric acid, water, and
short chain alcohols. This drug complex has the potential to either interchange some
portions of the hyclate with the similar PG/PEG composition of A6 or simply form a
larger complex with a drug/polymer conjugate. This conjugate would then, in theory, be
slower to diffuse out of the complex. This theory is reinforced by the slowing of the
release rate when A6 is used in the delivery systems.

While the exact mechanism of A6 is not fully understood, it is clear that additives can
have a great effect on drug release from the OC system. With this knowledge, other
additives, and their effect on the system, will be explored.

SW Polymer Additives
After the success of A6, the SW family of polymers was developed and synthesized.
These polymers are low molecular weight poly-ether-co-glycolide copolymers. These
polymers were tested for release, the results of which can be seen in Figure 4.9 on the
next page. These additives show even greater promise than the A6 polymers in achieving
linear release. The major difference between the A6 and SW polymers is the inclusion of
ether segments in the SW polymer. These segments are added through the incorporation
of PEG in the copolymer. A comparison of A6 and SW results can be seen in Figure 4.10
on page 77. The decreased hydrophobicity of the construct likely helps maintain the
hydrophilic drug. Perhaps most important in terms of SW effect on release, the entire
release profile for OC9 is seen in Figure 4.11 on page 78.
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Figure 4.9: The effect of the SW family of additives on release from the OC9
delivery system (n=3, error bars indicate 1 standard deviation)
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Figure 4.10: Comparison of A6 and SW2: effect on DOX release from OC9 (n=3,
error bars indicate 1 standard deviation)
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Figure 4.11: Release of DOX from OC9/SW2 system over 42 days with line of
best fit (n=3, error bars indicate 1 standard deviation)

From this graph it is apparent that SW additives can have a great effect on the release of
DOX from the OC system. A relatively linear release is achieved. As can be seen from
the best fit line in Figure 18, a linear fit garners a R2 value of 0.9861. This type of release
would be highly advantageous for systems requiring strict quantity control due to a
limited range of acceptable concentrations between the lowest efficacious dose and the
maximum tolerated dose.
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BTO3 Additive
The BTO3 additive is a tri-axial ε-caprolactone-based polymer.

This polymer was

studied to examine the effect of additive structure on release. As a tri-axial polymer,
BTO3 often behaves differently than the linear copolymers described so far.
Succinylation with BTO3 magnifies the effect of a potentially charged end-group on
release; the resulting polymer is denoted BTO3S. DOX release results from BTO3 and
BTO3S are compared to A6 in Figure 4.12.

Figure 4.12: Effect of doxycycline release from OC4 system and release differences
between BTO3 and BTO3S (n=3, error bars indicate 1 standard deviation)
Both BTO3 polymers appear to be superior in relation to A6 (OC4A), demonstrating
reduced release, even in the fast releasing OC4 system. This reduction is likely due to the
triaxial nature of BTO3 and the hydrophobic nature of the BTO3. However, BTO3 was
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not suitable for large scale use in the system, as the caprolactone nature of the polymer
caused injection difficulties, imparted a waxy, brittle quality to the final construct, and
the mass loss for BTO3 is a wide window. Also, it is interesting that the succinylation
(OC4BS) of the BTO3 creates a wide variation in release. This could be attributed to
either (1) the lack of efficiency of the succinylation process, or (2) disturbances in the
polymer matrix from the increased charge presence. If the succinylation process is not
efficient at affecting the BTO3 polymer homogenously, the charges/end group
modification will vary from sample to sample, effecting variability as seen in this sample.

Diluent Effect on Release
As the OC polymers require a diluent for administration, the effect of this diluent should
be examined to completely understand the system. Polyethylene glycol with Mw of 400
(PEG 400) was chosen as the initial diluent for many reasons. PEG 400 is a liquid
polymer with a relatively low viscosity, is already used in many medical applications,
and is effectively miscible with the OC polymers with the application of heat. The
experimental diluent G4A (acetylated PEG 400) was compared to PEG in many instances
to determine the effect of end-group chemistry on depot formation and subsequent
release.

Figure 4.13 illustrates the difference of release on the OC9 system when

comparing G4A and PEG 400 as the diluent portion.
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Figure 4.13: Comparison of DOX release from OC9 system between PEG and G4A
diluents (n=3, error bars indicate 1 standard deviation)

The difference in release between the two profiles, while not profound, is apparent in the
initial two week period of release. While potentially helping the system in terms of
injectability and shelf-life prior to injection, G4A appears to disrupt the initial release
kinetics of the system. This finding was further clarified by studies, see Figure 4.14,
conducted in OC4 systems, which are already plagued by quick release as seen earlier,
but exacerbated by the use of G4A. Also in this graph can be seen the effect of G4S.
G4S is succinylated PEG 400, which was prepared to visualize the effect on release of a
different end-group modification.

86

Figure 4.14: Effect of doxycycline release from OC4 systems with varied diluents (n=1)

As can be seen, neither G4S or G4A appears to be a promising replacement for PEG 400
when striving to attain linear release from the OC delivery systems. These end group
modification techniques appear to cause the diluent to carry more drug as they evacuate
the depot formation. This is seen through the almost tenfold increase in burst between
the PEG and modified diluents. From this data it stands that PEG-based diluents are
capable of use with the system, but unmodified PEG should be used to best achieve linear
release. Next, it is logical to explore the effect of varying diluent component percentage
of the OC system. The effect of a 50/50 polymer/diluent system versus a 67/33 system is
seen in Figure 4.15.
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Figure 4.15: Comparison of DOX release from OC9 system between a 67/33 and 50/50
system of G4A (n=3, error bars indicate 1 standard deviation)

Interestingly, these samples show that, while there is little initial burst difference between
more or less diluent, there is a significant effect on release in the early days of the system.
This leads one to believe that the larger diluent percentage may not be able to fully
evacuate the depot initially, but rather, when it is able to escape, carries a large amount of
drug with it. The 50/50 composition, while injectable, does not control release as well as
the polymer dominant system. Also, due to the reduced polymer presence, the 50/50
mixture does not form as repeatable or as strong depot following injection as the higher
polymer percentage compositions.
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Blending of OCs and Effect on Release
The OC polymers were also designed to be amenable to blending processes. Polymer
blends are often employed to derive properties from multiple polymers into a single
polymer. Blends differ from copolymers as the polymeric chains and units are not
themselves covalently joined, but rather remain separate while acting as a single unit. In
essence the OC delivery system as a whole is a blend of OC polymer, diluent polymer,
and polymeric additive. The next logical step of this progression is to examine the effect
of blending multiple OC polymers together to examine the effect on release.

The

blending is simple and achieved through physical mixing of the OC polymers, both
together in the same step of the system preparation as the diluent. To first examine the
feasibility of blending, a screening study was performed using OC4 and OC9 as test
subjects.
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Figure 4.16: Comparison of DOX release from blended OC systems (n=3 for OC9 and
OC4 release, error bars indicate 1 standard deviation)

From this data it can be seen that blending is indeed possible as all three of the release
curves for the blends fall approximately between the release curves for OC4 and OC9.
Blending has many benefits to systems such as the OC system. Primarily it allows the
development of a more modular platform without the use of complex polymerizations.
Also, secondary properties including injectability and depot formation can be tuned to a
specific application. The successful blending of the OC polymers opens interesting doors
to tailorable delivery systems for individual applications. The ability to use multiple
drugs for myriad indications provides an opportunity for personalized medicine. This
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idea is discussed in more detail in Chapter 5. Following this success, blending was
examined more thoroughly through a series of tests.

Figure 4.17: Comparison of DOX Release from OC Blends (n=3, error bars indicate 1
standard deviation)

Figure 4.17 reveals that 1:1 blending of OC4 and OC9 with OC2 produces release curves
which contain characteristics of both of the single polymer systems. The OC9 blend still
releases at a lower rate than the OC4 blend, but both blends show release similar to that
of OC2. Also, both releases still show acceptable repeatability and therefore blending
can be expected to combine characteristics of the composite polymers.
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Figure 4.18: Comparison of DOX release from OC blends of differing diluent
composition (n=3, error bars indicate 1 standard deviation)

Figure 4.18 shows the effect of diluent change in a blended system is similar to that of the
unblended or single system, specifically, the larger the diluent component, the higher the
initial release. From the gathered blending data it is reasonable to postulate that blending
OC polymers into a single system will result in hybridization of release profiles. These
blended results, following initial observation, appear to follow the results one would have
expected based on the data gathered from the single OC systems.
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Conclusion
Many methods to control a water soluble drug are presented in the context of the OC
system. These methods involve the manipulation of assorted variables within the system.
Release from the OC system has been shown from a quick 3-day release to an almost
linear release over 42 days. Such modularity with the OC system speaks to its potential
use as a platform technology.

If the OC system can be shown to be useful and

controllable with a variety of drugs, such a system could have many uses in a wide range
of applications in medicine.
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CHAPTER FIVE
RELEASE OF OTHER DRUGS FROM THE OC SYSTEM; USE OF REVERSE
PHASE HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY

Following the examination of doxycycline as a model drug, other drugs were considered
for release quantification, in conjunction with the OC system. Various bioactive agents
were investigated to show the system’s modularity and potential as a platform
technology. In these instances the ability to quantify drug release was vital. Accurate,
rapid and repeatable detection of pharmaceutical agents allows comparisons between
drug delivery constructs prior to in vivo studies as well as identification of therapeutic
levels in samples both in vitro and in vivo. Perhaps the foremost scientific method for
monitoring therapeutics is high performance liquid chromatography (HPLC).

HPLC allows clear and simple quantification of therapeutic presence in a sample, with an
inherent or induced chromophore, through the detection of bound specimen to the HPLC
column. Multiple drugs can be analyzed through this process; methods were developed
in this research for the pharmaceutics carboplatin, cefuroxime, clindamycin, dicloxacillin,
doxycycline, metronidazole, paclitaxel, and tobramycin. For each drug: (1) a brief
background is supplied, (2) a reverse phase HPLC method is described, (3) a standard
curve is presented to show the linearity of response for the proposed method within a
range of absorbances, and (4) release is examined from the OC4 system. This quick
releasing system was chosen both to illustrate the cross-utility of the OC polymers within
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the proposed system as well as to illustrate that most antibiotic regimens tend to be
shorter in duration than typical chemotherapeutic courses. Analysis of all drugs was
performed on a single HPLC apparatus, showing the flexibility of the technology as well
as the ability to analyze multiple compounds from one machine, allowing laboratories to
save costs on multiple machines and columns.

HPLC
HPLC is a widely used method to quantify the presence of a pharmaceutical solute in
samples.

This analytical method involves the injection of a sample into the

chromatographic column, which then retains the desired sample from the mobile phase.
The extracted and bound sample can then be analyzed through a variety of methods,
which involve the detection of a chromophore of the bound agent. HPLC analysis is
superior to other forms of ultraviolet-visible (UV-Vis) quantification due to its ability to
clearly quantitate material as well as remove material interaction issues inherent in other
processes281. Despite this distinct advantage, HPLC is a very difficult process, with
variables such as temperature, column choice, mobile phase composition and mobile
phase pH being essential to consider282.

Column choice is a crucial variable, influencing the efficacy of an HPLC method.
Columns are offered in a wide variety of types and sizes, but can generally be divided
into normal phase and reverse phase columns. These column names relate to the manner
in which the desired solute is removed from the mobile phase and drawn to the analytical
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column283. Reverse phase is by far the more prevalent technology at present and involves
hydrophobic columns and aqueous-based mobile phases. Commonly used columns in
reverse-phase HPLC (RP-HPLC) include C8 and C18 columns.

Column choice

parameters have been covered in the literature282,283 and, as RP-HPLC is by far the more
prevalent, the terms RP-HPLC and HPLC will be used interchangeably in this text as
they are in literature.

Following the choice of column type, HPLC methods fall into two groups based on
analytical scheme. These two schemes are referred to as isocratic and gradient methods.
Isocratic methods refer to the use of a single mobile phase composition for the entire
analysis, whereas gradient methods refer to methods which use a changing composition
through the process. Isocratic analysis has been considered faster, however gradient
analysis allows higher throughput284, better resolution284, and separation of multiple
compounds in a single sample285. For these reasons gradient analysis is often employed
in analytical settings where applicable. When choosing a gradient method, the mobile
phase is of great concern. Mobile phases in RP-HPLC usually involve water, acetonitrile,
and/or methanol and sometimes a dopant agent such as triethanolamine or triflouroacetic
acid (TFA)282. Because of the large amounts of variables present in such systems,
method development is quite difficult and results in many methods for analyzing the
same drug286. For this reason, it is important to select and/or develop the best method for
a given application’s indication.
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HPLC System and Parameters
A single HPLC apparatus was used for the detection of all drugs, allowing limited
maintenance and ease of work flow interruption between projects. The column used was
a Waters Symmetry® C18 5 µm 4.6 x 150 mm column, and the pump was a Waters 1525
binary HPLC pump.

The pump and column were coupled with a Waters 2996

Photodiode Array Detector (PDA) for analysis. All mobile phases were first filtered
through a Waters four channel in-line degasser prior to injection into the pump housing.
Mobile phases used were HPLC grade water with 0.1 % TFA and acetonitrile (ACN)
with 0.1% TFA. A Waters 717plus autosampler was employed to allow multiple sample
injection. Software for analysis was Waters Empowerer Pro. The flow rate was set at 1
ml/min. Note that the methods are described by percentage of ACN mobile phase,
omitting the complimentary percentage of HPLC composition in the mobile phase.

Method Development: A General Outline
Methods for each drug were generated specifically for the provided HPLC apparatus. A
drug solution of greater than 0.1 mg/ml was prepared in mobile phase solution. If a given
drug was not soluble at 0.1 mg/ml, the highest concentration found in lab was used.
Sample was then analyzed on the described HPLC apparatus through a gradient method
of 5% ACN to 95% ACN over a period of 20 minutes (Figure 5.1).
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Figure 5.1: A 5-95% run of cefuroxime on HPLC
The 5% to 95% range was chosen to limit usage of the end ranges of column absorbance
and therefore enhance the lifetime of the column. This HPLC trace provides a general
range for the determination of the second method attempt. The location of the peak in the
original run determines the second run, which is prepared with a range of 15% change in
ACN over a space of 10 minutes (Figure 5.2).
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Figure 5.2: A first attempt at a “15% method” for cefuroxime
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The mobile phase composition was adjusted until the major eluent peak appeared more
than 5 minutes after the solvent injection peak, to be assured of peak resolution from the
solvent front (Figure 5.3).

Figure 5.3: Acceptable method for cefuroxime analysis on HPLC
Once this resolution was achieved, the method was determined to be acceptable.
Analytical wavelength for each drug was determined as the wavelength which
corresponded with the maximum absorbance response compared to the baseline noise for
the sample peak, as provided by the attached photodiode array detector. Following
development of the method, the process was analyzed for reproducibility through
generation of a standard curve consisting of at least five varying injection quantities; an
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R2 value of greater than 0.99 was achieved when correlating micrograms injected and
absorbance reported.

Antibiotics, the OC System, and Clinical Need
The following sections each discuss a different bioactive agent. Each of the drugs
discussed was chosen for method development based on clinical need. The myriad drugs
tested show the modularity of the system, and therefore the platform nature of the OC
technology. A brief outline is given of the clinical use of the drugs as well as an
overview of HPLC methodology for each. The results of method development and
release testing from the OC system are presented subsequently. Finally, release eluents
of applicable drugs were efficacy tested with a model cell line to illustrate release and
maintenance of drug activity.

Cefuroxime
Cefuroxime is a member of the cephalosporin family, which displays activity against
both gram-positive and gram-negative bacteria287. The drug is usually well tolerated by
patients and is used to treat a wide range of diseases, especially those where
penicillinases are not advised for use or the patient exhibits allergic symptoms.
Cefuroxime is a well-characterized drug with many methods for quantification and has a
prominent chromophore with peak UV absorbance in the 270-280 nm range, making it
acceptable for HPLC analysis288. The drug is usually used in salt form, with cefuroxime
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sodium being prevalent. This form is very hydrophilic and, for this reason, RP-HPLC
can be used to quantitate drug presence in solution samples.

Cefuroxime sodium salt was determined to be best analyzed through the gradient method
of 20 to 35% ACN over a time of 10 minutes. With this method, a peak was found at
approximately 7.25 minutes.

The best absorbance for analysis for this peak was

determined to be 275 nm. A standard curve was prepared of a sample solution injected at
different injection volumes, resulting in an R2 value of 0.9999. A standard curve is
shown in Figure 5.4.

Figure 5.4: Cefuroxime standard curve at 275 nm
From this standard curve, cefuroxime was determined to be analyzable using HPLC,
allowing quantification of release from the OC4 system. Batch release studies were
prepared in a method similar to previously described for doxycycline testing. Gels were
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prepared used G4A as a diluent.

A 2%, 5% and 10% loaded cefuroxime gel was

prepared, to allow comparison of drug content effect on release. The results of the batch
release studies can be seen in Figure 5.5.

Figure 5.5: Release of cefuroxime from OC4 gel systems (n=3, error bars indicate 1
standard deviation)
Interestingly, cefuroxime was initially quickly released from the OC4 depot. This is not
surprising, given it is a highly water-soluble drug and the OC4 system is quick releasing.
Also, no additives were used to control this burst. Even with this quick drug release, a
portion of the loaded drug was released over a period of days following the initial burst in
each of the three cases. Drug release was also relatively similar across specimens of each
of the experimental groups. More drug was found in cumulative release measurements
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than was expected in the theoretical mass calculations of the system, which points to a
need to better control the mixing process of the gel preparation. Perhaps most interesting
is that as the weight percentage of drug in the gel was increased, the rapidity of drug
release was also increased. This phenomenon was seen in other experimental groups, as
well as in doxycycline, and points to the fact that drug concentrations must be tightly
controlled in depot formulations.

To further illustrate the ability of this system to combat infection, eluents were sampled
and used to treat populations of microbiological growths. Staphylococcus aureus (S.
aureus, Moltox) was used as a model organism. S. aureus was thawed in tryptic soy
broth and cultured at 30 ºC according to manufacturer instructions. All eluent samples
were removed from storage (2 – 8 ºC). At that time, 15 µL of each sample was added to 5
milliliters of broth inoculated with S. aureus according to 0.5 McFarland Standard (0.05
absorbance reading). Controls consisted of 5 milliliters inoculated broth. Samples were
vortexed gently and placed into a 30 ºC incubator overnight. After approximately 24
hours, relative absorbance was recorded for each sample using a spectrophotometer (600
nm wavelength). Relative absorbance was related to percent inhibition through use of
controls. Results from 2% cefuroxime eluents can be seen in Table 5.1.
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Table 5.1: Percent Inhibition of S. Aureus by Cefuroxime Eluents
Eluent ID

Drug

Control A
Control B
Day 1
Day 2
Day 3
Day 4
Day 5.5
Day 7

Cefuroxime
Cefuroxime
Cefuroxime
Cefuroxime
Cefuroxime
Cefuroxime

Measured Concentration
after Dilution (HPLC)
ug/mL
4.15
0.84
0.33
0.12
0.08
0.02

Raw Optical
Density (OD)
0.982
1.013
0.052
0.323
0.662
0.795
0.88
0.991

%
Inhibition
0.00%
0.00%
94.79%
67.62%
33.63%
20.30%
11.78%
0.65%

As can be seen from Table VI, clinically relevant cefuroxime dosing is delivered over
multiple days, with the best effect coming on days 1 and 2. Inhibitory effects are seen
until approximately day 7.
Clindamycin
Clindamycin is a lincosamide that is finding a wider use in today’s clinic due to the wide
range of efficacy for the drug289. It can be used to treat infections from staphylococcal to
anaerobic to even some protozoal infections290. Clindamycin is supplied as a hydrophilic
salt, traditionally as a hydrochloride. With this enhanced solubility, RP-HPLC is often
employed with detection around 200 nm289, 290. Clindamycin HPLC methods are usually
isocratical289,
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while gradient methods are useful especially as clindamycin is often

used in combination treatments285.

The clindamycin hydrochloride analysis method was determined to be 20% to 35% ACN
over a period of 10 minutes. With this method, a peak was found at approximately 8.15
minutes. This peak was also determined to have a best absorbance for analysis at 210
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nm. A standard curve was then prepared of a sample solution injected at different
injection volumes, resulting in an R2 value of 0.99999. A standard curve is shown in
Figure 5.6.

Figure 5.6: Clindamycin standard curve at 210 nm

From this work, clindamycin was chosen for release analysis using OC4. Clindamycin
was examined at concentrations of 5 and 10% by weight. Results can be seen in Figure
5.7.
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Figure 5.7: Release of clindamycin from OC4 gel systems (n=3, error bars indicate 1
standard deviation)
Clindamycin shows a well-controlled release from the OC4 system following the inherent
first day release of the system. Again, a higher release of drug occurred than was
expected through theoretical measurements, pointing to a need to better control and
monitor mixing conditions. These promising results were further confirmed through
microbiological testing in a manner consistent with that outlined previously. The results
of testing the 10% loaded gel system can be seen in Table 5.2.

107

Table 5.2: Percent Inhibition of S. Aureus by Clindamycin Eluents
Eluent ID
Control A
Control B
Day 1
Day 2
Day 3
Day 4
Day 8

Drug
Clindamycin
Clindamycin
Clindamycin
Clindamycin
Clindamycin

Concentration
ug/mL
21.9
3.5
2.2
2.2
4.0

Raw OD
0.876
0.944
0.124
0.582
0.124
0.154
0.123

% Inhibition
0.00%
0.00%
86.37%
36.04%
86.37%
83.08%
86.48%

From this data it can be assumed that a clinically relevant amount of efficacious
clindamycin is delivered over a period of 7 days when the 10% loaded clindamycin gel is
observed in vitro.

Dicloxacillin
Dicloxacillin is a modern member of the penicillin family. It is penicillinase-resistant,
allowing use in indications where other members of the group are not effective291. It is a
highly polar compound which causes difficulty with extraction in many processes292.
Previous work with this drug has involved reverse phase columns and has used detection
wavelengths between 220 and 240 nm291-294.

Dicloxacillin salt monohydrate was determined to be best analyzed through the gradient
method of 45 to 60% ACN over a time of 10 minutes. With this method, a peak was
found at approximately 7.33 minutes. This peak was also determined to have a best
absorbance for analysis at 225 nm. A standard curve was then prepared of a sample
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solution injected at different injection volumes, resulting in an R2 value of 0.999. The
standard curve is shown in Figure 5.8.

Figure 5.8: Dicloxacillin standard curve at 225 nm
Following the development of this standard curve, dicloxacillin was examined for release
from the OC4 system. Dicloxacillin was tested at 2, 5 and 10 weight percent loadings.
This data is displayed in Figure 5.9.

109

Figure 5.9: Release of dicloxacillin from OC4 gel systems (n=3, error bars indicate 1
standard deviation)
The data, shows that dicloxacillin was released from the OC system. Also, dicloxacillin
was analyzed via microbiological assay. The concentrations measured from the 5%
weight loaded eluents are listed in Table 5.3.
Table 5.3: Percent Inhibition of S. Aureus by Dicloxacillin Eluents

Eluent ID
Control A
Control B
Day 1
Day 2
Day 3
Day 4
Day 5.5
Day 7

Drug
Dicloxacillin
Dicloxacillin
Dicloxacillin
Dicloxacillin
Dicloxacillin
Dicloxacillin

Measured Concentration
after Dilution (HPLC)
ug/mL
12.98
3.22
1.23
0.56
0.26
0.08
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Raw
OD
0.954
0.967
0.07
0.204
0.021
0.075
0.314
0.639

%
Inhibition
0.00%
0.00%
92.71%
78.76%
97.81%
92.19%
67.31%
33.47%

This data suggests that a clinically relevant amount of efficacious dicloxacillin is
delivered over a period of 7 days when the 5% loaded clindamycin gel is observed in
vitro.

Metronidazole
This cytostatic drug has a wide range of uses within the clinic.

Metronidazole is

prescribed for conditions ranging from rosacea to bacterial vaginosis295. The drug has
also been shown to sensitize tumors to radiotherapy, beginning its use in oncology296.
For these conditions, the drug is often carried within a gel297, with release from the gel
being an important experimental variable. For this reason, HPLC is often employed as
the drug is water soluble, has a strong chromophore, and is used in the described wide
variety of applications. Detection for this drug is performed over a wide range, from 250
to 350 nm295-297.

Metronidazole-free base was determined to be best analyzed through an isocratic method
of 3% ACN over a time of 10 minutes. Gradient methods proved difficult due to the high
water solubility of the drug, and a percentage outside the 5 to 95 % preferred range was
required. This method exhibits the effectiveness of isocratic methods with the described
HPLC apparatus. With this method, a peak was found at approximately 7.30 minutes.
This peak was also determined to have a best absorbance for analysis at 275 nm. A
standard curve was then prepared of a sample solution injected at different injection
volumes, resulting in an R2 value of 0.999. The standard curve is shown in Figure 5.10.
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Figure 5.10: Metronidazole standard curve at 275 nm
Following the successful standard curve development, release was quantified from a 5
and 10 weight percentage OC delivery system. The results of this analysis can be seen in
Figure 5.11.
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Figure 5.11: Release of metronidazole from OC4 gel systems (n=3, error bars indicate 1
standard deviation)
Metronidazole demonstrated one of the better controlled releases from OC4 amongst the
drugs observed; it was released in a controlled manner for longer than 1 week. Also, the
opposite effect of drug loading was seen with metronidazole, where the higher loaded
drug amount had a slower release profile than the lower, 5%, loaded construct. These
differences are interesting to note as this drug was analyzed as a free base rather than a
salt. Also, the drug involved has an inherent charge. Both of these facts can affect drug
release and should be considered when using data from one drug to predict release of a
different drug.
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After these release profiles were prepared, metronidazole was examined by
microbiological assay as well. Metronidazole is not effective at inhibition of S. Aureus so
a different model organism was employed.

Veillonella parvula was employed, as

metronidazole is known to be effective against this bacterium, which is present in many
systemic infections. Veillonella parvula was thawed in reinforced clostridial broth and
cultured at 37 ºC with 5.0% CO2 present, according to manufacturer instruction. Broth
was inoculated with V. parvula according to 0.5 McFarland standard (0.05 absorbance
reading). Inoculated broth (5.0 milliliters) was placed in a culture tube for each sample
tested. Each eluent was stored at 2 - 8ºC prior to experimentation. All samples were
removed from storage; 100µL of each sample was placed into a separate culture tube
containing V. parvula (prepared as described earlier). Samples were vortexed gently and
placed into a 37 ºC incubator with the presence of 5.0% CO2 overnight.

After

approximately 24 hours, relative absorbance was recorded for each sample using a
spectrophotometer (600 nm wavelength). Relative absorbance was related to percent
inhibition through use of controls. The results from both 5 and 10 weight percent
metronidazole eluents can be seen in Table 5.4.
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Table 5.4: Percent Inhibition of V. parvula by Metronidazole Eluents
5% Samples
Eluent ID
Control A
Control B
Day 1
Day 2
Day 3
Day 6
Day 7
Day 8
Day 9

Drug
Metronidazole
Metronidazole
Metronidazole
Metronidazole
Metronidazole
Metronidazole
Metronidazole

Eluent ID

Drug

Control A
Control B
Day 1
Day 2
Day 3
Day 6
Day 7
Day 8
Day 9

Metronidazole
Metronidazole
Metronidazole
Metronidazole
Metronidazole
Metronidazole
Metronidazole

Concentration
ug/mL
68.8
18.3
8.7
5.2
1.0
0.5
0.2
10% Samples
Concentration

ug/mL
88.7
28.0
26.7
19.1
6.3
4.1
4.7

Raw OD
1
1.016
0.04
0.062
0.036
0.05
0.487
0.973
1.072
Raw OD
0.452
0.49
0.011
0.011
0.026
0.001
0.035
0.018
0.02

% Inhibition
0.00%
0.00%
96.03%
93.85%
96.43%
95.04%
51.69%
3.47%
-6.35%
% Inhibition
0.00%
0.00%
97.66%
97.66%
94.48%
99.79%
92.57%
96.18%
95.75%

As can be seen from this data, an efficacious amount of drug can be delivered for up to 1
week from a 5% loaded depot, and a 10% loaded depot delivers efficacious levels of drug
for longer than 9 days.

Paclitaxel
Taxanes, and paclitaxel in particular, have taken a leading role in chemotherapy over the
recent decade. This expansion of use is largely due to the efficacy of paclitaxel in
treatment of a wide range of solid tumors298. This drug moves to block mitotic activity
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by interference with the formation of microtubules299, thus preventing cancer cell
division. However, due to the prevalence of significant side effects, paclitaxel is almost
always used in a low dose compared to that of other bioactive agents300. This need for a
precise drug concentration combined with the important nature of the drug indications,
make paclitaxel an important drug for quantification. HPLC is uniquely suited for the
low levels of drug used as well as the common use of paclitaxel with other drugs and
excipients such as Chremophor EL®298,301. The hydrophobic nature of the drug does
necessitate different mobile phase ratios than the other described drugs, but hydrophobic
columns can be used and detection is usually around 230 nm298-301.

Paclitaxel-free base, free of excipients, was determined to be best analyzed through the
gradient method of 50 to 65% ACN over a time of 10 minutes. With this method, a peak
was found at approximately 6.55 minutes. This peak was also determined to have a best
absorbance for analysis at 230 nm. A standard curve was then prepared using a sample
solution injected at different injection volumes, resulting in an R2 value of 0.999. The
standard curve is presented in Figure 5.12.
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Figure 5.12: Paclitaxel standard curve at 230 nm
This method was repeatable; however paclitaxel release in aqueous systems reveals poor
results. The largest obstacle to testing in similar manners to those used for previous
drugs lies in the lipophilic (non-water soluble) nature of the drug. For this reason, release
studies performed in the traditional manner resulted in sub- analyzable amounts of drug
release. It was postulated that the introduction of a non-aqueous solvent component, such
as ACN, into the release medium could allow visualization of paclitaxel release by
increasing the solubility of the drug in the medium. However, this idea was rejected due
to two main concerns; (1) the drug medium would be less indicative of the physiological
environment and (2) the introduction of additional solvents could adversely affect the
degradation of the OC system and exhibit an inaccurate release profile.

For these

reasons, the only applicable method of analysis was that of an extraction study. To
perform an extraction study, the extraction must be clarified and the efficiency must be
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determined. To determine the extraction efficiency of paclitaxel from the OC system,
three samples were prepared of 1 weight percent paclitaxel. Each of these samples was
then submersed in 5 milliliters of acetonitrile (ACN) and placed in a 37°C incubator
shaker. After 90 minutes the gel and drug were completely dissolved. A volume of 5
milliliters of HPLC grade water was added to each of the extraction vials. Following this
addition, the solution became a cloudy mixture due to solubility issues with both the drug
and polymer.

Subsequently, the samples were centrifuged at 10,000 RPM for 20

minutes. A clear supernatant was achieved, extracted and filtered through a 0.45 µm
Acrodisc® filter. These three eluents were then run in triplicate for each extraction using
the HPLC. Results of this analysis are shown in Figure 5.13.

Figure 5.13: Paclitaxel extraction efficiency study (n=3)
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Figure 38 shows that the paclitaxel extraction is relatively consistent with an efficiency of
42.85 percent (n=9, 1 standard deviation = 1.04). However, due to this low efficiency it
was decided to postpone studies where release would be determined by the remaining
drug in the gel.

Tobramycin
Many serious infections within the body require specialized antibiotics. Tobramycin is
often used to combat difficult infection such as osteomyelitis302 and other serious gram
negative bacillary infections303. This aminoglycoside is similar chemically to a sugar
complex but presents challenges for HPLC analysis as it lacks a chromophore302.
Because of this, pre-column derivatization techniques are often employed to make this
drug visible to an associated UV detector303,304. The method used in this test is similar to
that presented by Lai of Varian chromatography systems304. The pre-column
derivatization employed involved the preparation of a 0.25 w/v solution of tobramycin in
a 60/40 v/v ACN/water solvent. Simultaneously, a solution of orthopthaladehyde (OPA)
in 0.1 v/v% 2-mercaptoethanol/borate buffer (0.4 M, 10.4 pH) was prepared. These two
solutions were combined in a 1:1 volume ratio and allowed to react for 1 hour. At 1 hour,
the solution was filtered through 0.45 µm filter and analyzed via HPLC.

Tobramycin sulfate salt was successfully prepared for HPLC analysis through a precolumn derivatization as described. A pre-column derivatization was required due to the
lack of a chromophore on the tobramycin structure. Analysis of the tobramycin complex

119

was determined to be best performed using the gradient method of 5 to 95% ACN over a
time of 20 minutes. With this method, a peak was found at approximately 6.15 minutes.
This peak was also determined to have a best absorbance for analysis at 254 nm. Other
peaks, resulting from the agents involved in the pre-column derivatization, present in
chromatogram were omitted from standard curve analysis.

A standard curve was

prepared of a sample solution injected at different injection volumes, resulting in an R 2
value of 0.99. The standard curve is displayed in Figure 5.14.

Figure 5.14: Tobramycin standard curve at 254 nm
The reaction used to prepare the HPLC visible complex is time sensitive, so analysis of
tobramycin visibility was performed. A sample was tested for response at 30, 90, 150
and 320 minutes post reaction initiation. Results can be seen in Figure 5.15. From this
information it was determined that analysis should take place in the first hour following
the pre-column derivatization to achieve the best results and a repeatable method.
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Figure 5.15: Tobramycin time complex stability study
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Following this evaluation, a release study was performed for tobramycin from OC4 at
both 5 and 10 weight percent mixtures. The results of this work can be seen in Figure
5.16.

Figure 5.16: Release of tobramycin from OC4 gel systems (n=3, error bars indicate 1
standard deviation)
The results from this study are interesting in that, while tobramycin releases from the OC
system, the results are different than those of any other drug studied. Before much is
made of the difference however, it should be noted that much of the abnormality can be
explained by the necessary use of a pre-column derivatization. The wide variation seen
in post day 1 samples can easily be explained; samples could not be run at the exact same
time due to the use of an auto sampler system. For this reason, sample 1 and sample 3 of
a triplicate were analyzed as much as an hour apart which, as seen in Figure 40, can cause
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considerable differences in HPLC values reported. Also, the day 1 results should be
carefully scrutinized as the low values point to difficulty with the pre-column
derivatization. With these items in mind, tobramycin can be incorporated into and
released from the OC system, but a better method of analysis should be found to allow
quantification.

Carboplatin
Carboplatin is highly interesting for this work due to the fact that it is both a
chemotherapeutic and a water soluble drug. As discussed previously in Chapter 1,
carboplatin is employed in a wide array of tumor treatments and would be an ideal model
chemotherapeutic for such a platform technology. Interestingly, carboplatin and the other
platinum drugs show great difficulty in analysis through RP-HPLC. Their hydrophilic
nature, as well as the platinum complex, makes binding to hydrophobic C8 and C18
columns difficult. With this knowledge in hand, a reverse-phase HPLC method was
sought for carboplatin.

Carboplatin-free base was determined to be best analyzed through an isocratic method of
5% ACN over a time of 10 minutes. Gradient methods proved difficult due to the high
water solubility of the drug, and a percentage of 5 % was required. Even with this highly
aqueous mobile phase, the retention times were barely resolved from the solvent peak.
With this method, a peak was found at approximately 2.22 minutes. Despite attempts at
other mobile phase compositions, no better resolution was found.
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The peak was

determined to be capable of analysis and was determined to have a best absorbance at
240 nm. A standard curve was then prepared of a sample solution injected at different
injection volumes, resulting in an R2 value of 0.9999. A standard curve is shown in
Figure 5.17

Figure 5.17: Carboplatin standard curve at 240 nm
Despite the difficulties with resolving the carboplatin from the solvent injection front, an
excellent standard curve was prepared, lending credence to the acceptability of the
method. This success lead to the incorporation of carboplatin in an OC9/PEG system
both with and without the additive SW2. These samples were subjected to a typical
release study, and the results of this study can be seen in Figure 5.18.
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Figure 5.18: Release of carboplatin from OC9 gel systems (n=3, error bars indicate 1
standard deviation)
These exciting results indicate that carboplatin can be released from the OC systems and
the release can also be controlled. Both groups have an acceptable amount of standard
deviation within readouts at specific time points, but more interesting is the fact that the
inclusion of the SW2 additive in the system allows a semi-linear release of the drug,
visualized alone in Figure 5.19.
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Figure 5.19: Release of carboplatin from an OC9/PEG/SW2 gel system (n=3, error bars
indicate 1 standard deviation)
This release shows great promise for treatments of narrow therapeutic range drugs such
as chemotherapeutics. Specifically, if this in vitro data could be carried over into an in
vivo setting, such a treatment could allow a constant exposure of the tumor to drug as
well as a mitigation of side effects seen by the patient.

Conclusion
The data presented in this chapter points to the potential of the OC system as a platform
delivery system.

Multiple drugs, antibiotics, antifungals, and chemotherapeutics, of

much different chemistry were incorporated and released from the OC system. Also seen
form the data, multiple drugs can be analyzed from a single HPLC apparatus.
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Furthermore, each drug has a well-defined and reproducible analytical method. Each
method has been determined to be efficient for the respective drug, and robust with an R 2
value of greater than 0.99.

Of most value within this chapter are the in vitro release results of carboplatin from the
OC9/PEG/SW2 system.

This relatively linear release over 3 weeks, a typical

chemotherapeutic regimen, could provide a very important approach to treatment of solid
tumors. However, this data is not valuable if it cannot translate into in vivo models.
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CHAPTER SIX
THE USE OF THE OC SYSTEM TO DELIVER CARBOPLATIN IN AN ATHYMIC
NUDE MOUSE MODEL

In previous chapters the ground work has been laid for the translation of a promising in
vitro performing system to the in vivo setting. The idea of being able to introduce a
system capable of continuously delivering a chemotherapeutic agent while maintaining
efficacious drug concentrations holds great promise in the field of chemotherapy. To
examine the potential efficacy of the OC system, further testing was required beyond the
previously described characterization. This chapter outlines the use of the OC system in
delivering carboplatin in an athymic mouse model.

The Murine Model and the Relation to the OC System
The murine model is a typical model used for early in vivo studies. A very robust and
cost-effective model, mice can be used for protocols ranging from toxicity studies to
tissue response visualization. For use with the OC system, the vision is to use a murine
model for a tumor response study. Specifically, tumors will be induced in the mice,
treated with the OC system, and monitored for tumor response. While a straight-forward
plan, many variables must be considered, starting with the specific mouse strain upon
which to perform studies.
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The mouse strain chosen for this work was the Athymic Nude-Foxn1nu (Harlan
Laboratories, USA). These mice present an interesting combination of attributes as they
both lack a thymus, and therefore lack lymphocytes, but also are hairless. Both of these
attributes are important for the proposed study and present advantages over other strains.
The genetic manipulation of the mice to prevent the formation of a thymus is valuable for
induction of tumors. The lack of T and B cells prevents the mouse immune system from
attempting to prevent the adherence of tumor cells implanted into the body. Accordingly,
attribute cancer cell lines such as OVCAR-3 can be injected into athymic mice and
tumors can be cultivated in the subjects305. This tumorigenicity allows early stage tumor
treatment models before proceeding to larger, more costly, animals.

The induced genetic mutation of athymic mice is the hairless nature, or nudity, of the
strain. This lack of hair is valuable in that it allows direct observation of the epidermis of
the subject. This can be valuable for monitoring of injection sites and surrounding tissue
for inflammatory and immune response as well as the observation of subcutaneous
artifacts. These artifacts can be either the induced tumors or devices implanted by
researchers. In the instance of this work, the formation and macroscopic stability of the
OC system can be observed in vivo following subcutaneous implantation. Female mice
were selected because an ovarian cancer cell line was used. For all these reasons, the
female Athymic Nude-Foxn1nu murine model was chosen for this work.
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Following the identification of the animal model for this project, the assays were
identified.

First, following inducement of tumors, tumor progression would be

monitored. Many studies use methods such as fluorescing tumor lines and systems such
as the IVIS XR Lumina (Perkin-Elmer, USA) to quantify the relative florescence
between animals. The use of this system however has many potential pitfalls, and a
simpler, transcutaneous caliper measurement was identified.

Not only is this method

more cost effective and robust, it has been employed successfully by our group in past
studies306. For these reasons, tumor size as measured by ellipsoid caliper measurement
was chosen for tumor progression monitoring. The ellipsoid caliper method includes the
taking of 6 diameter measurements around the circumference of the ellipsoid shaped
object and the averaging of these 6 measurements to reach a single composite value.

Gel permeation chromatography (GPC) was chosen to monitor the degradation of the OC
system following implantation. Dichloromethane (DCM) was identified as a solvent
capable of solubilizing the majority of the OC system and allowing quantification of
molecular weight before and after insertion. Also, histology was chosen to help identify
activity in the tumor microenvironment. Following excision and immersion fixation in
formalin, tumors were to be processed and examined using two immunohistological
stains. Apoptosis and cell proliferation at time of excision were identified as important
variables showing tumor behavior and progression.

Apoptosis imaging would be

performed using the TUNEL assay kit (Invitrogen, USA) and cell proliferation analysis
would be performed using the PCNA visualization kit (Invitrogen, USA).
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With thought given to the eventual study, a pilot study was conducted to address what
level of drug would be tolerated by the animals when delivered through the OC system.
This preliminary work was also used to verify the assays chosen for the study as well as
evaluate other potential metrics.

Preliminary Work
To most effectively treat the induced tumors, the maximum tolerated dose of carboplatin
capable of being delivered from the OC system was determined. Such a dose would be
the optimal concentration to use for the treatment of animals where a tumor had been
induced as it would be the dose most likely to have an effect on the tumor without
causing systemic morbid toxicity to the subjects within the study. For this reason a five
mouse study was undertaken to determine an approximation of the therapeutic window.

To determine the concentration required, the literature was surveyed for the median lethal
dose (LD50). Literature values generally agreed with mouse intravenous LD50 values of
around 90 mg/kg and intraperitoneal LD50 values of 150 mg/kg307. As the desired site of
implantation was subcutaneous, the intraperitoneal value was chosen as a better predicate
value to use for these studies. Thus, using a value of 150 mg/kg and an average female
mouse mass of 20 grams (0.02 kg), an LD50 value was calculated at 3 mg per mouse.
Using this as the estimated LD50 values, mice were chosen to be tested at 15 mg, 10 mg
and 3 mg if the 15 and 10 mg mice showed toxicity.
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Initially, the 15 mg subject was chosen for initial testing. To calculate the volume of OC
system with 5 wt% carboplatin required to reach this dosage, the density of the OC
system was measured. This measurement yielded a density of 1.142 g/ml. Using this
density, a 250 microliter injection was calculated to deliver 14.275 mg of drug. Due to
the limitations of the injection system in quantitating delivery, a 250 µl injection was
accepted as a reasonable amount to allow accurate delivery rather than an injection for
exactly 15 milligrams of carboplatin.

With the injection volume calculated at 250 µl, gel preparation was initiated. OC9, PEG
400, SW2 and carboplatin were all removed from storage and placed in a chemical hood.
Materials were mixed in a method similar to previously described methodology with
minor exceptions. In order to allow injection into the mice subjects, sterilization was
necessary. Sterilization by filtration is a common method for injectable elements, but the
viscous nature of the OC system makes this problematic, time consuming, and wasteful.
Gamma irradiation and ethylene oxide sterilization are options for larger scale batches
and studies, but were not viable scenarios for the given work. For this reason, dry heat
sterilization was chosen. All polymeric components were checked for viability at 130°C,
and found to be acceptable at this temperature. The literature available for the drug
carboplatin did not indicate heat stability at this temperature and was therefore not
subjected to the heat sterilization, but rather carboplatin was assumed sterile due to the
nature of the drug. Thus, the polymeric components were subjected to a 130°C 1-hour
cycle in a dry heat oven. Following this treatment, the gel was immediately transported
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to an isopropyl alcohol and irradiation sterilized biosafety cabinet and allowed to cool to
room temperature. Following cooling, the carboplatin was introduced into the mixture
and the system was mixed thoroughly by pestle and mortar within a sterile field.
Following homogenous mixing, the system was transferred to the non-needle end of a
sterile 1 ml BD luer-lok syringe capped with a 16 gauge needle and allowed to flow to fill
the syringe.

Material was transferred the following day to Godley-Snell Research Center (GSRC,
Clemson University, Clemson, SC) where the subjects were housed.

Mouse A was

anesthetized and injected in the subcutaneous space of the abdomen. The injection was
performed without issue and the system visibly formed subcutaneously through the
hairless mouse skin, see Figure 6.1. Seepage through the injection site was present but
minimal. The mouse regained consciousness and was mobile and unaffected.
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Figure 6.1: Image of depot deposited in Mouse A (24 hours post injection)

The subject was checked and examined on day 1 and no ill effects were noted. The
mouse was visually checked each subsequent day with no illness noted.

However, on

day 7 the animal was found dead. The mouse had perished quickly and the corpse was in
poor condition when found. Internal organs were misshapen and swollen; the liver of
mouse A is presented in Figure 6.2 as an example.
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Figure 6.2: Liver from Mouse A swollen and visibly diseased
The depot was not present in large quantities in the necropsy and therefore is postulated
to have dissipated. Such rapid dissipation would explain the rapid exposure of the
internal organs to carboplatin and the subsequent rapid deterioration of the subject. No
signs of systemic infection were seen by the attending physician and cause of death was
suggested as carboplatin toxicity.

Interestingly, the mouse appeared to have been

accepting nourishment until close to the time of death. The mouse had only lost ~2
grams despite the poor condition of the corpse, and the gastrointestinal (GI) tract showed
fecal emboli throughout the entire system. This further strengthens the argument of a
rapid degeneration of the animal.

135

In order to examine the behavior of the gel system in vivo, HPLC analysis of the
harvested remnants was employed. For this analysis the small amount of gel retrieved
from the corpse was placed in a vacuum box and dried to a constant weight. Once
constant weight was achieved, the gel/tissue complex was subjected to a drug extraction
as described in previous chapters. The resultant eluent was then analyzed via HPLC. A
peak was seen at a retention time similar to the carboplatin in vitro studies, indicating that
there was 0.39 mg of carboplatin in the 82.4 mg sample (0.5 wt%). However, there were
issues with the given analysis. These issues include: (1) the assumption that the excised
mass was entirely gel, which is unlikely as tissue was intimately joined to the gel sample,
even after cleaning and (2) the assumption that the entire peak response seen in the
chromatogram was carboplatin. To address concern (2), a photodiode array detector
(PDA) was employed to compare the nature of the response peak generated to that of the
standard curve employed in the in vitro studies. A response of “not identical” was the
outcome of the PDA spectrum comparison. This does not indicate that the compounds
represented by the PDA are completely different, simply that the compounds cannot be
claimed as identical. Hence, the carboplatin extracted from the gel could be degraded
from the in vivo experience, or even the extraction preparation, and caused an altered
PDA signal. Regardless, the HPLC analysis of this gel was determined to be non-viable
and the decision was made to perform future evaluation of gel using GPC to examine
molecular weight effects over the course of the study.
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Following the toxic exposure visualized in mouse A, mouse number B was treated with a
175 µl injection of the OC system. This treatment equated to roughly 10 milligrams of
dose, or greater than 3x the literature LD50. The OC system was prepared in standard
fashion as previously described; however, a smaller gauge needle (20 gauge) was
employed to create a smaller incision site in the subject. Injection was also performed in
the rear flank in this subject, to attempt to limit the body cavity volume exposed, see
Figure 6.3.

Figure 6.3: Hind flank placement of polymer depot (Mouse B 6 days post implantation)
Mouse B awoke from treatment and was ambulatory within seconds. The subject never
experienced any evident ill effects from treatment and survived with no weight loss for
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28 days. No signs of infection or injection site irritation were seen during study. The gel
depot was evident and in place at the injection site for the complete duration of the study,
see Figure 6.4. No internal organ damage was visualized upon scheduled necropsy.

Figure 6.4: Mouse B following euthanasia (21 days post implantation)
Following this promising result, mouse C was treated with an identical 10 mg delivery
sample. The mouse appeared healthy for the first 5 days but exhibited mass loss at day 5
and was found to have lost ~40% of body mass by day 6. The subject was euthanized
according to Institutional Review Board protocol using isofluorine gas. During necropsy
no internal organ damage was noted nor any signs of infection. The polymer depot was
also perfectly formed and intact, as can be seen in Figure 6.5.
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Figure 6.5: Mouse C at sacrifice (6 days post implantation)
The cause of death was deemed to be lack of nutritional intake, with probable cause being
lack of appetite as a side effect of treatment.

Following this subject loss, mice D and E were treated with 50 µl injections, which
deliver approximately 3 mg, or roughly the published LD50, of the drug. Neither mouse
exhibited any ill effects throughout the study and maintained weight for the duration of
the study. Both polymer depots remained formed in the hind flank for the duration of the
study. Following sacrifice, liver and kidney from mouse D were immersion-fixed in
formalin (10%), and subsequently prepared for staining. Both organs were stained with
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hematoxylin and eosin (H&E) to allow visualization of organ response at a cellular level
in both tissues.

Images taken from both organs can be seen below at objective

magnifications of 10x and 40x in Figure 6.6.

Figure 6.6: In clockwise order from top-left (1) Mouse D kidney at 40x (2) Mouse D
kidney at 10x (3) Mouse D liver at 10x (4) Mouse D liver at 40x
As can be seen, and confirmed by a licensed pathologist, no evidence of toxicity is
evident. This indicates that the carboplatin released from the 3 milligram systems was
not distributed in large enough concentrations systemically to cause negative liver or
kidney response on a cellular level.
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To further understand the behavior of the OC system in this model, gel harvested from
mouse E was subjected to GPC analysis with DCM as the mobile phase. A physically
cleaned gel sample from mouse E was prepared along with four other samples via a
dissolution and filtration process (0.45 µm acrodisc filter). The other four samples
examined were (1) a remnant sample of the prepared gel that had not been subjected to
the in vivo environment, (2) a neat (polymer only) OC9 polymer sample, (3) a neat SW2
polymer sample, and (4) neat PEG400. As expected, the glycolide heavy SW2 would not
dissolve in the DCM solvent of the GPC (a fluorinated solvent, such as
hexafluoroisopropanol (HFIP), based GPC system was not available for analysis).
Therefore prior to filtration, insolubilized material could be visually seen in both OC
system samples and the neat SW2 sample. Following filtration all samples were run.
Results can be seen below.

Figure 6.7: GPC results of OC system following mixing but prior to injection
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Figure 6.8:GPC results of OC system extracted from murine model

Figure 6.9: GPC results of neat OC9 polymer
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Figure 6.10: GPC results of neat PEG 400

Figure 6.11: GPC Results of neat SW2 (no peak present)
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From these results it can be seen that the OC system does experience degradation when
subjected to the in vivo environment. The neat OC9 polymer exhibits an Mn of 14185
while the post-in vivo sample exhibits an Mn of 8393. This relates to the in vitro
degradation numbers referenced in earlier chapters and suggests that the polymer
composition is biodegradable. Also, the PEG peak present in the pre-in vivo gel (Figure
50) is not present in the post-in vivo gel. This strongly indicates that the PEG had left the
construct. Figure 54 is included to show that all variables have been considered and that
the post-in vivo peak cannot be any polymer other than OC9, as SW2 is not visible on a
DCM GPC. A summary of the results of the preliminary work are presented in Table 6.1.
Table 6.1: Results of Preliminary Animal Studies
Mouse

Dose

Result

A

15 mg/ 250 µl

Found dead on day 7. Massive apparent
damage to internal organs.

B

10 mg/ 175 µl

Survived entire 21 days with no ill effects.

C

10 mg/ 175 µl

Euthanized on day 6 following ~40% loss of
body mass due to lack of nutrition.

D

3 mg/ 50 µl

Survived entire 21 days with no ill effects.

E

3 mg /50 µl

Survived entire 21 days with no ill effects.

From this work it was evident that no clear window of treatment could be identified,
especially in this statistically underpowered study. While promising results were seen
with mouse C and in the 3 mg mice, no clear window of dosing was found. Also, a
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dosing above 3 milligrams would raise the probability of success in tumor response
model studies. For this reason a larger pilot study was conducted.

Cell Culturing and Testing of Efficacy with Carboplatin Eluents
Concurrently with other preliminary activities, OVCAR-3 cells were acquired from
ATCC (USA). The specific cell line acquired was NIH:OVCAR-3, ATCC catalog No.
HTB-161. These ovarian adenocarcinoma cells were sourced originally from humans
and have been used in multiple studies for xenografts over the past 30 years305. In one
study provided by ATCC, tumors developed within 21 days at 100% frequency (5/5) in
nude mice inoculated subcutaneously with 107 cells. These cells are a biosafety hazard 1.
The cells were provided frozen and thus were thawed to allow for use. Thawing was
performed by gentle agitation in a 37°C water bath, and vial was decontaminated using
70% ethanol. Vial contents were then transferred to a centrifuge tube containing 9.0 ml
complete culture medium and spun at approximately 125 xg for 5 to7 minutes. Pellets
were resuspended with medium prepared as per manufacturer’s instruction305. Medium
for this cell line was prepared through combining ATCC formulated RPMI1640 Medium
with 0.01 mg/ml bovine insulin and fetal bovine serum to a final concentration of 20%.
Cells were then incubated at 37°C in a 5% CO2. Medium was renewed every 2 to 3 days
during cell use.

Following the successful cultivation of cells, OVCAR-3 cells were plated at a seeding
density of 37,500 cells/cm2 in a 12 well plate. Once seeded the cells were exposed to free
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carboplatin in aqueous solution at a calculated 2x the half maximal inhibitory
concentration

(IC50).

The

cells

were

monitored

against

controls

through

photospectrometry. Using this methodology, a 66% decrease was seen in cell count
against the control. From this data it is reasonable to assume that the OVCAR-3 cells can
be cultured in sufficient numbers for implantation and will likely be susceptible to
carboplatin presence in vivo. The cell line was frozen for maintenance until a tumor
study could be mounted.

Full Pilot Study
In order to better define the upper threshold of the therapeutic window, a pilot study was
performed. In this study 20 mice were divided into 5 groups as seen in Table 6.2.
Table 6.2: Groups and Subjects for the Pilot Study
Groups

Mouse

Treatment

1

1,2,3,4

No treatment received

2

5,6,7,8

175 µl of unloaded OC system for
each subject

3

9,10,11,12

175 µl of 5wt% loaded carboplatin
(~10 mg dose)

4

13,14,15,16

150 µl of 5wt% loaded carboplatin
(~8 mg dose)

5

17,18,19,20

100 µl of 5wt% loaded carboplatin
(~6 mg dose)
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The study was conducted in such a way as to examine the OC system independent of
carboplatin, as well as at three levels of carboplatin loading. Thus, the OC system could
be ruled out of serious consideration as a toxin and the experimental variable, drug
loading, could also be examined.

To quantify differences between groups, four variables were identified for monitoring
during the proposed study. Animal mass, gel molecular weight, complete blood count
(CBC), and liver/kidney histology were all identified as important metrics of
performance. Animal mass was measured in grams weekly and at death as a measure of
health and nutritional intake. CBC testing was performed on animals where possible to
determine whether anemic conditions were present as a result of treatment as well as
immune response and lymphocyte presence in the circulating blood. GPC and histology
were performed on every animal as previously described in the preliminary studies.

A single batch of OC system was prepared for the entire animal study, using described
methodology. The delivery system had never been prepared on this scale before but no
significant issues were seen during preparation. Gel was divided into syringes for each
separate group. It should be noted that the placebo gel for group 2 was segregated prior
to the integration of the carboplatin to assure absence of the bioactive agent. All twenty
treatments were performed in succession and no significant difficulties were seen during
injection. Needles were not changed in between mice of the same group to preserve gel.
All animals awoke from anesthesia and showed no visible signs of impediment.
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No difficulties were seen until day 6 when two mice, #15 and #16 were found to have
expired overnight. In the next two days, Mice #11, 12, 19 and 20 were all either found
dead or euthanized due to veterinary concerns as per protocol. The remaining 14 mice
showed no signs of afflictions or weight loss, with many of the experimental mice
gaining weight as can be seen in Table 6.3. Within the table, groups are color coded for
easier identification.
Table 6.3: Subject Weights during Course of Study
Mouse

Initial Weight (g)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20

23
22
24
22
21
22
22
22
21
23
24
24
21
21
19
23
20
23
21
22

Weight Day 7
(or prior)
24
21
24
23
22
22
23
23
21
24
14*
16*
22
21
13ᵻ
16ᵻ
21
24
15ᵻ
13*

Weight Day 14

Weight Day 21

24
22
26
25
23
23
22
24
22
26
23
21
23
25
-

24
21
24
25
22
23
23
24
21
26
22
21
23
24
-

*Mice euthanized at or before day 7 – Weight taken at euthanasia
ᵻ Mice found dead at or before day 7- Weight taken when found
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GPC was used to examine the effect on polymer molecular weight following in vivo
implantation. This data can be seen in Table 6.4. It should be noted that there are no
values for group 1 as no polymer was present in these animals.
Table 6.4: Results of GPC Data from Mice Within The Study
Mouse Final Viable Day Molecular Weight (Mn)
1
21
2
21
3
21
4
21
5
21
9623
6
21
10433
7
21
9445
8
21
9832
9
21
1218
10
21
9465
11
6*
10488
12
7*
9082
13
21
1240
14
21
7654
15
6ᵻ
6910
16
5ᵻ
7582
17
21
7497
18
21
7683
19
7ᵻ
8470
20
6*
7571

Group Average (n=4)

-

9833.25

7563.25

5846.5

7805.25

*Mice euthanized ᵻ Mice found dead

The polymer groups which contained drug appear to have exhibited more degradation
than the other groups present in the study. This point can likely be attributed to the fact
that the presence of the bioactive agent lowered the local pH of the construct. A lower
pH is known to increase hydrolysis and hence hydrolytic degradation. Also, as the drug
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leaves the construct, the avenues and volume within the construct would increase,
allowing water access and increasing hydrolysis. Perhaps the next most interesting facet
is that the values of the polymer in the earlier perishing subjects does not vary
significantly from those of the mice that survived the entire study. This is interesting as
one would expect hydrolysis to be an ongoing process, with those samples exposed to
hydrolytic conditions longer to be more degraded. There are two samples, from mice 9
and 13, that were notably degraded but that did run the entire course of the study; these
are the exception to the rule. It would be interesting to see if the initial degradation is a
factor influencing the PEG evacuating the construct.

This could be a significant

contributor to the hydrolytic process and is a common variable across all groups.

All mice were exsanguinated at euthanasia and blood was provided to AnMed medical
center (Seneca, SC) for a complete blood count. Exsanguination was not possible with
the three mice found dead, as noted in Tables 6.5 and 6.6 on the following pages, which
show the results of the CBC analysis. Note that ‘-‘ indicates that no blood was collected
for a CBC and that ‘NR’ denotes complications with testing at the testing site resulted in
no value being reported.
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Table 6.5: Selected Results of CBC Testing (Cell Count)
Mouse

Treatment

Reference Values
Top End (1 STD)

Blood
Draw/CBC
4-12 Week
old Females

WBC

RBC

HGB

PLT

5.7

8.4

14.4

813.6

7.4

9.1

15.3

924

Low End (1 STD)
4
7.7
13.5
703.2
1
None
Yes
2.5
5.44
12.3
586
2
None
Yes
7.9
5.96
12.1
777
3
None
Yes
8
7.22
12.2
773
4
None
Yes
6.3
7.38
12.3
523
5
Polymer Only
Yes
6.3
7.18
13.6
230
6
Polymer Only
Yes
5.3
6.58
12.2
953
7
Polymer Only
Yes
5.9
6.98
13.2
954
8
Polymer Only
Yes
7.1
6.16
11.2
545
9
10 mg Carbo
Yes
4.1
6.86
13
NR
10
10 mg Carbo
Yes
5.9
6.44
12.1
440
11
10 mg Carbo
Yes
1.6
8.21
14.1
NR
12
10 mg Carbo
Yes
0.6
7.38
12.5
126
13
8 mg Carbo
Yes
4.9
7.92
15
805
14
8 mg Carbo
Yes
4.2
6.07
10.9
640
15
8 mg Carbo
No
16
8 mg Carbo
No
17
6 mg Carbo
Yes
5.4
6.19
11.9
675
18
6 mg Carbo
Yes
6.4
7
14.4
551
19
6 mg Carbo
No
20
6 mg Carbo
Yes
4.8
7.7
13
NR
Note: WBC = White Blood Cell count, RBC = Red Blood Cell count, HGB =
Hemoglobin count, PLT = Platelet count
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Table 6.6: Selected Results of CBC Testing (White Blood Cell Makeup)
Mouse
Treatment
Reference Values
1
None
2
None
3
None
4
None
5
Polymer Only
6
Polymer Only
7
Polymer Only
8
Polymer Only
9
10 mg Carbo
10
10 mg Carbo
11
10 mg Carbo
12
10 mg Carbo
13
8 mg Carbo
14
8 mg Carbo
15
8 mg Carbo
16
8 mg Carbo
17
6 mg Carbo
18
6 mg Carbo
19
6 mg Carbo
20
6 mg Carbo

Segs#
18.90%
0.6
2.8
2.6
2.6
1.8
3.3
2.4
2.8
1.3
1.2
1
0.5
1.2
NR
1.8
2.4
3

Lymph#
77.90%
1.9
4.7
4.9
3.3
4.5
1.7
3.1
0.1
2.7
4.7
0.6
0.1
3.6
NR
3.4
3.2
1.8

Mono#
1.50%
0
0.2
0.5
0.2
0
0.2
0.1
4
0.1
0
0
0
0
NR
0.2
0.6
0

Eos#
1.90%
0
0.2
0
0.1
0
0.1
0.3
0.2
0
0
0
0
0
NR
0
0.1
0

Note: Segs#= Neutorphil count, Lymph# = Lymphocyte count, Mono# = Monocyte count,Eos# =
Eosinophils count

Across this study, many items bear evaluation. From an experimental standpoint, it is
evident that larger animal groups are required. In group 4, the 8 mg dosage group, only a
single CBC was gained at the end of the study making comparisons across groups
difficult if not impossible. With that said, some observations can be made about the data
as a whole or between other groups. First, almost all mice, including the controls,
exhibited anemic or close to anemic counts of red blood cells (RBCs). This can likely be
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attributed to smaller sample groups but bears noting. Next, in the animals that perished
but from which blood was taken (#11,12, and 20), white blood cell (WBC) counts were
low, especially in #11 and #12. This could indicate an increase in carboplatin release into
the systemic tissue as the blood and circulatory system would be the primary carrier for
this systemic distribution. Also, there were reduced platelet counts in the samples from
#11, 12, and 20, further evidence of a potential systemic toxicity. Lastly and important to
note, Table 6.6 data shows a marked increase of non-lymphocyte WBCs. The presence
of large number of neutrophils (segs# as noted on CBC), monocytes, and eosinophils in
the polymer control group 2, indicates an immune response outside the normal range.
While signs of irritation and immune response were not noted macroscopically, it appears
that the introduction of large amounts of polymer into the mice did elicit an immune
response.

This should be carefully monitored in future studies to ensure the

biocompatibility of the system.

Finally histological analysis was conducted on all twenty mouse liver and kidneys. Mice
organs were excised and fixated using immersion techniques in 10% formalin. Tissues
were then trimmed, transferred to cassettes and embedded in paraffin wax. Samples were
then sectioned using a microtome and stained. Using H&E staining, tissue sections were
examined in conjunction with a licensed pathologist. No differences nor signs of toxicity
were seen between groups. Representative images from livers and kidneys of both
groups are provided below.
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Figure 6.12: Liver histology images (H&E staining) of mice 1, 5, 9, 16, and 20. Images
are displayed clockwise in numeric order with mouse 1 in the top-left corner. (10x
objective magnification)
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Figure 6.13: Kidney histology images (H&E staining) of mice 1, 5, 9, 16, and 20. Images
are displayed clockwise in numeric order with mouse 1 in the top-left corner. (10x
objective magnification)
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No signs of cellular toxicity was seen in either set of tissue samples. Normal cell activity
was seen in the liver sections provided as well as in the kidney samples. Some tubular
distortion can be seen in Figure 6.13, but this is not excessive for mouse kidney samples.

Discussion
This pilot study provides many answers as well as questions. The primary purpose of this
study, to delineate an upper threshold of treatment, does not appear to have been met.
Two mice perished from each of the experimental groups, which indicates that the LD50
of the treatment is somewhere within the range analyzed. There were not, however, large
enough groups of subjects to fully elucidate the differences between the experimental
groups. It can be assumed however that at 3 mg dosing, as seen in the preliminary work,
that reduced toxicity will be seen. Perhaps groups can tolerate 3 mg dosing from this
system with limited morbidity, which would already be an improvement over the free
drug LD50 of 3 mg.

The desired OVCAR-3 strain of cells was successfully cultured. In addition, the cells
could be cultured in the relatively large quantities required for injection and future tumor
xenografting.

Most importantly, the OVCAR-3 cells were shown in vitro to be

susceptible to carboplatin treatment, indicating that a murine model using an OVCAR-3
xenograft would be able to show quantitative tumor regression when exposed to
necessary quantites of carboplatin.
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While the “polymer only” injected mice showed no signs of outward distress, irritation,
or immune response, the CBC work on these mice showed some troubling facets. There
were signs of a systemic immune response (eosinophil presence, etc.) which indicate that
the materials were not fully tolerated. While no biomaterial can be fully inert, this is a
part of the system which bears further scrutiny. Despite the presence of the immune
response cells, no outward toxicity or debility was noted in the mice. It also bears noting
that the depot themselves were roughly 1% of the mouse’s body mass, and so would
represent a very large presence within the corpus. In future studies, histology can be used
at the implant site to examine tissue response and ensure that the immune response is not
overactive as well as check for the formation of fibrous capsules around the implant site.

The CBC results and histology samples are somewhat contradictory with respect to
systemic toxicity. From the liver and kidney H&E stains, both organs appear to be
functioning normally throughout the subjects of the study. However, the CBC white
blood cell and platelets values indicate a different picture of decreased viability. The
liver and kidney are described as the organs of toxicity for systemically distributed
carboplatin. However, in the study they appear to be healthy even in otherwise clearly
sick mice. The drug very likely is not being systemically administered in large quantities,
but likely overwhelming local tissue in cases of morbidity and causing organ damage in
those systems.
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This hypothesis is further encouraged by the observation of the GI tract in the mice that
perished within the study. All mice which were deceased prior to day 21 were found to
have significant damage to the GI tract, some with visible blood drainage from the anus
and vagina prior to death. These organs are among the areas most closely proximal to the
injection site, and if excess drug was diffusing outward from the site, without reaching
the liver or kidney, the GI tract would be a logical substitute for this toxicity. Also,
disruption of the GI tract could cause animals to cease eating due to disrupted appetite.
These mice in turn would become weaker and therefore become more likely to perish.

Furthermore, the mice were housed in pairs as behavioral science shows us that animals
housed with a partner for interaction will more accurately portray a real world scenario.
This is interesting when viewed in the light of the fact that all 6 mice that perished were
sets of two housed together. Nowhere in the study was there a pair of mice where one
died and one lived. Also, each of the mouse pairs that died were the later of the groups in
terms of injection, and a single syringe and needle was used to inject each mouse. This
could mean that gel and drug could have been left on the outside of the epidermis
allowing the cage mates to lick/ingest material in normal cleaning and social interaction.
The effect that these materials would have directly on the GI tract following ingestion is
difficult to predict but could explain the significant differences in GI health between
animals within the same groups.
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This last thought touches on another facet of the study that requires attention, the
injections into the animals. First, the use of the same needle for an entire group to save
polymer introduced significant variables throughout the study. If a single animal had
been diseased an entire experimental group could have been lost. Also, the luer-lock
syringe set-up did not allow accurate injection as the 1 ml syringe was graduated in 0.02
ml or 20 µl markings. This made it very difficult to attain the desired accuracy for the
system. Also, as these devices are designed for delivering liquids, the gels used in this
study did provide some issues mechanically with injection. Lastly, the gels required
loading the night before treatment and so the gel system was at rest in the needles
overnight prior to treatment. It cannot be assured that the system did not self-segregate
with the PEG 400 causing the preferentially held drug to migrate to the later injection
areas, resulting in a larger than anticipated actual carboplatin dose in the later mice of a
group. Further, it is assumed that the entire polymer system was mixed homogenously by
hand using a mortar and pestle. This process had been shown to be effective in previous
studies on a smaller scale, but could have been lacking with the large quantities required
for this study.

It should be noted that a significant assumption from this study was the actual LD50
value. No free carboplatin injections were performed and actual subcutaneous values are
not readily available in the literature. The calculated value based on the IP values from
the literature does provide an educated guess as to the value but intravenous mouse
values are significantly lower (almost ½) and as such the actual subcutaneous LD50 could
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be lower than expected. This would indicate that the system is more successful at
increasing the maximum tolerated dose than initially thought.

This research does indeed combine the fields of controlled delivery and chemotherapy in
a step forward. The results suggest an increase in the LD50, albeit unquantified, of
carboplatin tolerated within a mouse model. This in turn indirectly signifies that the drug
is released in lower quantities over a period of time, allowing the mouse subjects to better
tolerate the dose. The system however is far from complete with many significant
hurdles remaining to make a clinically viable product.

The results of the study bring to mind significant questions, not the least of which is the
validity of the mouse model.

The behavioral aspects alone discussed previously make

the results of the mouse model difficult to interpret, and also significant questions have
been brought to light recently about the translational ability of murine research308. The
subject is becoming so prevalent that it has made its way into the mainstream media,
recently appearing in the New York Times309. While this study incorporated an adequate
and cost effective model for early screening exercises, future project critical studies
should be performed on larger more clinically relevant models.

One significant drawback of the mouse model is the inability to test and model more
complex medical problems and treatments. For example, one method of chemotherapy
gaining wide spread acceptance in the clinic is transarterial chemoembolization, which
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murine models have difficulty modeling. In this procedure, the tumor is accessed through
the main arterial stalk which supplies the vasculature of the malignancy. The agent is
then delivered via a catheter, port or other device310. The agent then uses the vasculature
of the tumor itself to fully irrigate and perfuse the target and thus efficiently and
accurately deliver the desired pharmaceutical payload. This delivery route affords many
advantages over systemic delivery, such as efficiency and reduced systemic toxicity, as
well as offers the best opportunity to distribute the maximum amount of drug to the
malignant tissue. Multiple clinical studies have shown the potential efficacy of such a
procedure against hepatocellular cancer311,312. This procedure is performed traditionally
with a concentrated drug solution, but recently microparticles and drug-eluting beads
have been examined311,313. One such product, HepaSphere®, uses microspheres to not
only treat the malignancy but also to occlude the arterial blood flow and thus act as an
anti-angiogenic314. The ability to not only deliver desired agents as well as prevent
primary blood supply to a region makes polymeric systems attractive in this application.
Such methods hold great promise for treating mid to late stage cancers in difficult
locations such as the hepatic system and could provide excellent uses of the OC system.

Before larger scale studies can be undertaken it is important to understand that the system
still does require further screening in a mouse system. Further work should include a
statistically relevant (n=18) second pilot study of mice injected with a 3 mg dose of the
drug. This study would show the tolerance of this treatment and could be used to
distinguish some of the behavioral/study design variables discovered. Also, concurrently
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it is suggested to perform a maximum tolerated dose study aimed at the definition of the
upper threshold of the therapeutic window for free carboplatin injections in the
subcutaneous region for these mice. This would allow a better idea of the increased drug
delivery capability of the system.

Following this, and assuming an acceptable rate of tolerance of the 3 mg mice across the
group, the model would be ready for tumor bearing studies as suggested initially. Within
this study further assays could be included to fully elucidate the biological processes
under examination. First, histological analysis at the implant site is suggested, in addition
to the PCNA and apoptosis tumor histology. This assessment would be valuable for
understanding the cellular immune response elicited by the OC system. Also, organs
such as the gastrointestinal tract and ovaries, in addition to the liver and kidneys, should
be examined by histological means for signs of cellular distress. Also, perhaps most
importantly, pharmacokinetics (PK) work should be performed to attempt to quantify the
release of drug from the construct. If there is drug being released systemically, PK work
would allow quantification and would provide an idea of the release rate of the bioactive
agent from the construct.

Thus the OC system and similar technologies hold great promise in the ongoing battle
against cancer. Such technology could one day not only increase patient compliance and
reduce healthcare costs, but also make chemotherapy more tolerable to the patient. In
effect, patient tolerance could be made similar to the administration of any common
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antibiotic such as penicillin by maintenance of the drug concentration within the
therapeutic window. This dissertation is meant to be a humble addition to the wealth of
work being put forward in this area and, if successful in the improvement of one person’s
quality of life or even the addition of ten minutes with loved ones, would be well worth
the effort.
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CHAPTER SEVEN
CONCLUSIONS
The presented work serves to further integrate the fields of chemotherapy and controlled
delivery. The different combinations of the polymer, diluents and additives serve to
provide a range of release of a water soluble drug from 3 to greater than 45 days, thus
allowing the potential for addressing of a large number of clinical indications. Also, the
OC system was shown capable of release of the chemotherapeutic carboplatin in a
relatively linear manner over a period of 3 weeks, the course of a typical
chemotherapeutic regimen. Finally, the OC polymer system was examined in an in vivo
model and tolerance of the non-drug loaded system was exhibited. Preliminary work
helped to show that mice would tolerate levels of treatment greater than the 3 mg
indicated by the literature as well as the effective formation of the system in the
subcutaneous region of all 20 mouse subjects.

The system was also shown to be

absorbable and that the absorbable by-products did not cause death or incapacitation in
the 3 weeks of observation. A tumor cell line, OVCAR-3, was identified, cultured, and
proven susceptible to the chosen drug carboplatin in vitro at 2x the half maximal
inhibitory concentration.

The polymer system is shown to be promising for use with chemotherapy. The ability to
replace once per 3 week exposure regimens with a constant release of drug holds great
clinical potential. The ability to deliver drugs in this manner could not only increase
tumor response to chemotherapy and increase survival metrics in patients, but also limit
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the inherent side effects of such therapy. This work has laid the foundation for future,
larger, statistically significant studies wherein the tumor response of the system can be
measured.
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CHAPTER EIGHT
RECOMMENDATIONS FOR FUTURE WORK

The following items are suggested for future studies:



A larger, more statistically significant, maximum tolerated dose study should be
performed to further define the therapeutic window. A sample size of at least 18
specimens is suggested per group, with dosing ranging from 3 mg to 15 mg.



A study should be performed to determine the free carboplatin, e.g. not in the OC
depot, maximum tolerated dose to offer a quantifiable control group in future studies.



Other assays should be incorporated in future studies. These assays include:
o Immunohistochemistry at tumor sites to show cell proliferation (a metric of
tumor growth) and cell apoptosis (a metric of anti-neoplastic effectiveness).



Histology, including simple hematoxylin and eosinstaining, should also be performed
on other organs beyond those examined in this research, such as the brain,
gastrointestinal tract and ovaries as well as at the implant site.
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Phamacokinetics should be examined for carboplatin release in vivo to allow
quantification of release, examination of drug build-up in the surrounding tissue, and
systemic circulation of drug.



A larger animal model should be investigated for future animal studies.



The OC system should be examined for treatment of other conditions, such as
diabetes, patient compliance, inflammation reduction and long-term disease control,
where a sustained release of a pharmaceutical agent could be helpful.
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